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Abstract 
 
Andrew Philip Mayer, Ph.D. 
R.N. Adams Institute for Bioanalytical Chemistry 
Department of Chemistry, November 2010 
The University of Kansas 
 
 
 The focus of this research was the development of an animal model for local 
administration of 3-mercaptopropionic acid (3-MPA) in a chemically-induced epileptic 
seizure model using microdialysis sampling with simultaneous electrocorticography 
recording (ECoG).  Local administration of 3-MPA through the microdialysis probe was 
employed to elicit seizures in a localized brain region.  Delivery of 3-MPA to the brain 
and changes in amino acid and catecholamine neurotransmitters were monitored.  
Simultaneous ECoG recordings were made using a microdialysis probe with an internal 
Ag/AgCl electrode.  Local administration of a convulsant is important, as many clinical 
cases present with focal seizures.   
 Neurochemical and electrical activity were monitored in three separate brain 
regions: the striatum, hippocampus, and locus coeruleus.  3-MPA was administered 
through the microdialysis probe in one region, while control samples were collected in 
the other two.  These results demonstrated that unless two brain regions were connected 
via efferent or afferent pathways, administration of 3-MPA in one region had no 
neurochemical effect in the others.  In the region where 3-MPA was administered, an 
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increase in both glutamate, the main excitatory amino acid, and GABA, the main 
inhibitory amino acid, was seen.  In addition, an increase in both dopamine and 
norepinephrine was seen.   
 A multiple dosing regimen of 3-MPA was developed where 3-MPA was 
administered twice.  These results showed that there was an attenuation in the increase of 
glutamate and GABA during the second administration of 3-MPA, indicating a neuronal 
protective mechanism taking place to decrease the effect of the second 3-MPA 
administration.   
 Seizures were not detected using during local administration of 3-MPA using the 
microdialysis probes with an internal Ag/AgCl electrode.  This was not due to the 
ineffectiveness of the electrodes, as they detected seizures during systemic dosing of 3-
MPA.  It is possible that the number of neurons excited from the local administration of 
3-MPA were so limited that the signal was too small to be detected.   
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Chapter 1 
Introduction 
1.1 Epilepsy Overview 
Epilepsy is a neurologic disorder that affects 50 million people worldwide, 
approximately 1% of the world’s population [1].  Epilepsy is defined as two or more 
unprovoked seizures, meaning they are not caused by pre-existing conditions or 
environmental triggers such as low blood sugar or head trauma [1].  A seizure is a surge 
of electrical activity from the neurons in the central nervous system (CNS).  There is a 
fine balance in the brain between excitation and inhibition, as well as factors that 
propagate and restrict electrical activity.  While there are many animal seizure models 
with systemic dosing of convulsants, there are few where seizures are generated in a 
specific brain region [2].  This is important because 70% of new adult-onset epilepsy 
patients present with focal (local) seizures [3].  Generating seizures in a localized brain 
region will aid in the understanding of how it and other areas of the brain respond. 
 
1.2 Treatments for Epilepsy 
 The first course of therapy for epilepsy patients is anti-epileptic drugs (AEDs).  
Pharmacological treatments for epilepsy have many different mechanisms of action, 
including sodium channel blockers (carbamazepine and phenytoin), GABA receptor 
agonists (phenobarbital), GABA reuptake inhibitors (tiagabine), GABA Transaminase 
inhibitors (vigabatrin), and glutamate blockers (felbamate and topiramate).  While the 
knowledge of the mechanism of action of these drugs as well as an increase in the 
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discovery of new pharmacological treatments have increased over the years, only two-
thirds of the epileptic population are effectively treated by either one AED or a 
combination [4].  Figure 1.1 shows the percentage of the population who are seizure-free 
with AEDs.  Clearly there is a need for different treatments for the other one-third of the 
population.   
One such treatment is the ketogenic diet.  This diet is high in fat and low in 
carbohydrates and is often used for treatment of children with epilepsy.  Being a low-
carbohydrate diet, the body must then convert fats into fatty acids and ketones as opposed 
to burning carbs.  The ketones then pass into the brain and are used as fuel as opposed to 
glucose, which is reduced due to the decrease in carbohydrates in the diet. The increase in 
ketones is referred to as ketosis, which leads to a decrease in seizures.  The ketogenic diet 
has proven to be effective in one-half of the patients who use it [5]. A randomized study 
in children has showed a 75% decrease in the number of seizures after 3 months [6].  In 
adults, a modified version of this diet, known as the Atkins-diet was also effective at 
reducing seizures [7].    
A much more intrusive treatment for epilepsy is surgery.  Surgery requires 
removing the region of the brain which is causing seizures.  The benefits and risks must 
be considered, and surgery is an option mainly when other treatments have been 
exhausted.  However, surgery can be especially beneficial when the cause of seizures is a 
localized brain tumor or region of the brain where a stroke has occurred, or if the seizures 
are focal (localized to a specific region).  Recent studies have shown that in children 
undergoing surgery for seizures, 73% were seizure free after 3 years [8].  One other 
treatment is deep brain stimulation.  Here, electrodes are placed in the brain region where 
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seizures are occurring and electrical impulses are sent to the brain region to stop seizures.  
This has been performed is many brain regions, including the thalamus, cortex, basal 
ganglia, hippocampus, as well as stimulation of the vagus nerve [9, 10].  Brain 
stimulation has proven to be an effective treatment, with a 60-90% decrease in seizures in 
both animal and humans studies [9, 11]. 
 
1.3 Overview of animal seizure models 
1.3.1 Electrical and chemical  kindling models  
Animal models of epilepsy are invaluable in that they are a tool that allows for the 
study of modes of seizure onset, neurologic changes during seizure events, and new 
pharmacologic tools for seizure prevention.  There are generally two types of animal 
seizure models.  The first is the kindling model and the second are chemically-induced 
models.  The kindling model can be further broken down into two sub-categories, those 
that are electrically stimulated and those that are chemically-induced.  The electrical 
stimulation kindling model was first developed by Goddard in 1967 [12].  He found that 
daily stimulation of the amygdala portion of the brain by low intensity currents results in 
an increase in electrical discharges over time.  These electrical discharges have been 
shown to cause spontaneous seizure events [13].  Similar to electrically generated 
seizures, kindling can be induced by subsequent injections of chemical convulsants.  
Animals are injected daily with small doses of a chemical convulsant below the seizure 
threshold.  Over several days, the animal becomes more susceptible to these low doses 
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and seizures are generated.  There are several studies using pentylenetetrazol (PTZ) as a 
convulsant in kindling models [14-16].   
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Figure 1.1 Effectiveness of treatment by AEDs [4, 17]. 
	   6	  
 
1.3.2 Chemically-induced seizure models 
The more common seizure models are those that are chemically-induced.  The 
majority of these models work by upsetting the excitatory/inhibitory balance in the brain.  
Convulsants work on both glutamate and GABAergic receptors.  Agonists of glutamate 
receptors work by increasing glutamate, the major excitatory neurotransmitter in the 
brain, leading to abnormal electrical discharges.  Examples of chemically-induced seizure 
models are those developed using kainic acid that act on ionotropic glutamate receptors 
[18-20] and homosysteic acid which works on metabotropic glutamate receptors [21-23].  
Drugs that work on GABAergic receptors (GABAA and GABAB) act by decreasing the 
amount of GABA, the main inhibitory neurotransmitter in the brain.  There are also 
seizure models which work by altering the synthesis and metabolism of GABA.  
Glutamic acid decarboxylase (GAD) is the enzyme which converts glutamic acid to 
GABA by decarboxylation.  3-mercaptopropionic acid is a well established chemical 
convulsant which inhibits GAD, thus increasing glutamate and decreasing GABA 
concentrations [24-28].   
There are advantages and disadvantages for each seizure model, however 
chemically-induced models have several useful advantages.  Seizure duration and 
intensity can be modulated by the concentration of the convulsant that is administered as 
well as the means by which it is dosed.  Higher concentrations will more than likely lead 
to more intense seizures.  Giving a single dose (whether it be sub-cutaneous, intra-
muscular, or intra-venous) or multiple doses will determine the time course of seizures.  
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The kindling model takes longer for seizures to develop as opposed to seizures occurring 
after several minutes with an intravenous dose.  Additionally, seizures generated by 
kindling are less predictable, making it difficult to compare neurotransmitter changes 
when compared to a chemically-induced model where the concentration of convulsant 
can be held constant, and thus seizure intensity and duration are relatively constant.   
Regardless, a seizure model with a well studied mode of action is necessary to continue 
the discovery of AEDs and other therapeutic strategies for seizure maintenance.   
 
1.4 Electrophysiology recording 
 There are two types of electrophysiology recordings typically used.  The first is 
electroencephalography (EEG).  In EEG circular electrodes are placed on the top of the 
scalp.  EEG plots the voltage difference between two electrodes on different regions of 
the scalp.  The EEG voltage is a summation of all the electrical activity surrounding the 
scalp where the electrodes are placed.  EEG is extremely sensitive to body movements 
and these artifacts must be removed prior to analysis.  In addition, the scalp creates a 
barrier between the brain and electrode which results in a decrease in signal.   
The second method of electrophysiology recording is electrocorticography 
(ECoG).  These measurements are made by drilling a hole in the scull so that an electrode 
can be placed on the cortex.  The recording mechanism is similar to EEG, where the 
voltage difference between two electrodes is measured.  ECoG, however, provides more 
spatial resolution than EEG.  The electrodes can be placed in various brain regions, and 
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can be used during and after surgery to monitor brain activity and to determine if surgical 
removal of epileptic tissue was successful.   
 
1.5 Microdialysis Sampling 
 Microdialysis is an in vivo analytical sampling technique which measures the 
concentrations of unbound compounds in the extracellular space of various tissues.  
Microdialysis can be used to monitor the concentrations of endogenous compounds as 
well as exogenous compounds that have been dosed.  In addition to being a sampling 
technique, microdialysis can be used to administer compounds into tissue as well.  Since 
its inception, microdialysis has become a popular sampling technique in neurologic 
studies, and has gained popularity in pharmacokinetic (PK) and pharmacodynamic (PD) 
studies in various tissues [24].   
 The first study based upon the idea of in vivo dialysis was performed by Bito et al. 
in 1966.  In this study, a dialysis sac filled with 6% dextran in saline was placed into 
subcutaneous neck tissue of dogs.  The concentrations of free amino acids were measured 
based on the theory that the concentration of free amino acids were at a steady-state 
between the cerebrospinal fluid (CSF) and plasma.  Since concentrations of the free 
amino acids would change rapidly in the plasma and thus would be hard to measure, it 
was thought that by placing the sac in the CSF for 10 weeks prior to analysis one could 
measure the “average” concentrations of free amino acids due to the steady-state 
equilibrium between the plasma and dialysis sac [29].  There have been many advances 
in the technique, which have decreased the size of the sampling region as well as 
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coupling it to various other techniques.  Delgado et al. in 1972 developed the “dialytrode” 
by fusing two stainless steel shafts together to form inlet and outlet tubing as in a push-
pull cannula with a polysulfone membrane at the tip to be used in long term studies in 
awake monkeys [30].  This design was modified in 1974 by Ungerstedt et al., where thin 
dialysis fibers were used that could be lowered into the brain for sampling [31].  The 
release of dopamine following amphetamine dosing was monitored in this study.  
Microdialysis has also been used in conjunction with behavioral studies, to monitor and 
correlate physiologic and neurologic changes [32, 33].       
 
1.5.1 Theory of microdialysis sampling 
 Microdialysis is an in vivo analytical sampling technique that is based upon the 
principal of larger scale dialysis.  Compounds diffuse down their concentration gradient 
across a semi-permeable membrane according to Fick’s Law.  An isotonic solution, 
containing ions of similar concentration to those found in the targeted tissue, but void of 
the analytes of interest, is perfused across the membrane.  This solution, called the 
perfusate, flows using a syringe pump at typical flow rates of 0.1-5 µl/min.  Analytes in 
the extracellular space diffuse across the membrane and are collected from the outlet of 
the probe in a solution termed the dialysate.  Unlike large scale dialysis, an equilibrium is 
not achieved in microdialysis, rather a steady-state concentration gradient is rapidly 
established.  The dialysate contains the free (unbound) fraction of the analyte in the 
extracellular space and is also free of large molecules, such as proteins, which are 
excluded due to the molecular weight cut-off of the membrane.  Microdialysis can also be 
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used for introducing a drug to the tissue.  In this case, the perfusate contains the drug, 
which diffuses across the membrane into the extracellular space.  Here, a drug can be 
introduced to the tissue while simultaneously monitoring the changes in analyte 
concentration which can be collected in the dialysate.  Figure 1.2 demonstrates the theory 
of microdialysis.   
 
1.5.2 Microdialysis probe designs 
 Microdialysis probes come in a variety of different designs/geometries depending 
upon the application.  When performing experiments in the brain, a concentric/rigid 
probe with a cannula is used.  Since the brain is a heterogeneous tissue, a probe is needed 
that allows for high spatial resolution.  The concentric design was first developed by 
Zetterstrom et al. [34].  Figure 1.3 shows the design of a concentric rigid probe.  The 
membrane is typically between 0.5-4 mm in length and has an outer diameter of 240-350 
µm.  When implanted in the brain, a rigid guide cannula is used to hold the probe in place 
and is then held to the skull with dental cement and screws.  The second type of probe 
has a linear design.  Linear probes are used for sampling in homogenous tissues including 
the heart, liver, stomach, intestines and muscle [35].  In the linear probe design, the 
microdialysis membrane is placed between two pieces of polyamide tubing.  Each end of 
the membrane is glued to the polyamide tubing using ultraviolet glue.  The length of the 
membrane can be modified dependent upon the tissue in which it is being implanted.  The 
third type of probe design is a flexible cannula.  This type is mainly used for sampling in 
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blood vessels, but has also been used in tissue such as the liver [36, 37].  Figure 1.4 
shows the flexible cannula and linear probe designs.   
 The other factor that plays a role in probe design is the membrane type.  
Membrane length and physical/chemical properties of the membrane such as the 
molecular weight cut-off will play a role in sampling.  Membranes can be made from 
various materials including polycarbonate (PC), polyarylethersulphone (PAES), 
cuprophan, and cellulose acetate [36].  Due to the variety of chemical moeties on the 
analytes of interest, recovery/delivery can be greatly improved by selecting the correct 
membrane. 
 
1.5.3 Microdialysis calibration methods 
 When using microdialysis for quantitative determination of an analyte in the 
extracellular space, the relative recovery of the analyte across the probe must be known.  
Equilibrium cannot be reached between the perfusate and tissue due to the constant flow 
of the perfusate through the dialysis probe.  Under normal perfusion conditions recovery 
does not reach 100% and thus the relative recovery of the analyte must be determined.  
Relative recovery can be calculated using equation 1.1. 
 
(1.1) 
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 The concentration of the analyte in the perfusate will always be less than the 
concentration of the analyte in the extracellular space (ECF).  The relative recovery of the 
analyte can be improved by modifying several key factors.  One factor is the perfusion 
rate of the dialysate through the probe.  The slower the perfusion rate, the greater the 
recovery of the analyte.  Another factor is the composition and molecular weight cutt-off 
size of the dialysis membrane.  Relative recovery increases with the length of the 
membrane.  This factor can be used to your advantage, where the length of the membrane 
can be maximized to increase recovery of analytes in low concentrations.  The one caveat 
to that is that the membrane length must not be larger than the target sampling site (this is 
especially crucial in brain experiments).  Selecting the correct membrane composition is  
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Figure 1.2 Microdialysis theory [38]. 
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Figure 1.3 Rigid cannula microdialysis probe design for brain experiments [39]. 
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Figure 1.4 (A) Flexible cannular microdialysis probe design and 
(B) linear microdialysis probe design. 1=polyamide tubing, 
2=semi-permeable membrane, 3=MRE tubing, 4=UV glue junction 
[17]. 
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also important, as studies have shown that recovery of analyte can vary as much as 20% 
depending on the membrane of choice [40].  In addition, the molecular weight cut-off 
(MWCO) of the membrane can affect recovery, as can the sampling temperature of the 
microenvironment and complexity of the sample matrix.   
 A simple experiment to determine the relative recovery of an analyte across the 
microdialysis membrane can be done in vitro.  The microdialysis membrane is placed in a 
container containing a solution that mimics the extracellular fluid of the target tissue, 
such as artificial cerebral spinal fluid (aCSF) in the case of the brain.  The solution is 
warmed to 37ºC and constantly stirred.  The vial contains a known concentration of the 
analyte and the perfusate contains no analyte.  Dialysate samples are collected and the 
concentration of these samples are analyzed and compared with the concentration in the 
vial.  However, due to the static and heterogeneous nature of the environment in the brain 
or other tissue, in vitro recovery cannot be equated with in vivo recovery.  Other factors 
that make this comparison difficult are metabolism, vascularization of the tissue, and 
reuptake into cells [41].  In vitro probe recoveries have been calculated in other studies 
where the probe is placed in an agar solution to more closely mimic the environment in 
the brain [42].   
 Due to the limitations of in vitro microdialysis recoveries, in vivo calibration 
methods must be used to obtain quantitative data.  The only true way to obtain in vivo 
recoveries is with the “no-net-flux” method described by Lonnroth et al. in 1987 [43].  In 
this experiment, the expected concentration of the analyte in vivo is bracketed on both 
sides with varying concentrations of the analyte in the perfusate.  When the concentration 
of the analyte in the perfusate is greater than the in vivo concentration, the analyte will 
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diffuse across the membrane and into the tissue.  Likewise, if the concentration of the 
analyte is lower in the perfusate, then in vivo the analyte will diffuse into the 
microdialysis probe.  A plot is constructed with the net change in the concentration of the 
analyte in the dialysate (y-axis) plotted versus the concentration of the analyte in the 
perfusate (x-axis).  This results in a linear relationship which allows the determination of 
the actual concentration in the tissue, when there is “no-net-flux” of your analyte from 
the perfusate to the tissue.  This method is time consuming, and is not practical for 
studies where the concentration of the analyte changes rapidly in vivo, such as 
neurotransmitters in the brain.  Justice et al. described a variation on “no-net-flux” where 
a single concentration of analyte was perfused through various subjects as opposed to one 
subject being perfused with varying concentrations [44].  The data from all the subjects 
can then be pooled and plotted similar to the “no-net-flux” experiment.  This provides a 
determination of the extracellular concentration with respect to time. 
 A simpler method for determination of probe recovery is that of calibration by 
delivery or retrodialysis with an internal standard.  In this method, a known concentration 
of the analyte is placed in the perfusate.  The relative delivery of the analyte is calculated 
using equation 1.2.  
 
(1.2) 
 
The recovery of the analyte can then be estimated based on the principle that the delivery 
across the probe membrane is the same as the recovery.  This method, however, does not 
	   18	  
allow for the determination of probe recovery throughout an experiment, and thus 
whether certain biologic conditions (ischemia/reperfusion etc.) change probe recovery.  
This can be done by retrodialysis, where an internal standard, often the exogenous 
compound antipyrine, is placed in the perfusate and monitored over the time course of the 
experiment [45, 46].  Studies by Lunte have shown that the calibration methods of no-
net-flux and retrodialysis show similar results for most analytes [47]. 
 The last method for in vivo probe calibration is the flow rate variation method 
[48].  In this method, the concentration of the recovered analyte is plotted against the 
flow rate of the perfusate.  When the graph is extrapolated to zero, the concentration of 
the analyte as well as the probe recovery value can be estimated.  The downside to this 
experiment is that with low flow rates, the amount of time needed to collect sufficient 
dialysate for analysis affects the temporal resolution.  At very low flow, recovery is 
essentially 100% [49, 50]. 
  
1.5.4 Advantages and limitations 
 Microdialysis has many advantages over more conventional techniques such as 
tissue slicing and homogenates, as well as blood and urine sampling.  Microdialysis 
allows for site-specific sampling of compounds in the extracellular space.   This can be 
done in anesthetized as well as awake and freely moving animals.  This is an advantage 
over tissue slices where the tissue of interest is removed and sampling is done ex vivo, 
removed from its native environment.  Tissue homogenates, while allowing for sampling 
of compounds in both the intracellular and extracellular space, typically only allow for 
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one time point per animal.  With microdialysis, one can obtain multiple time points for 
each animal, and each animal can be used as its own control.  This greatly reduces animal 
to animal variability as well as the number of experiments that need to be performed.  
Microdialysis also provides excellent spatial resolution, which is important when 
sampling in a heterogeneous tissue, such as the brain, where the neurotransmitter 
concentrations can vary widely in two spatially close regions.  Sample analysis, whether 
by LC or CE, can be done with no sample cleanup, due to the molecular weight cut-off of 
the membrane removing proteins from the sample.  This is also advantageous since 
enzymes, which may degrade the analyte of interest, are also removed from the sample.  
Compared with blood and urine serial sampling, there is no net fluid loss with 
microdialysis.  By dosing through the microdialysis probe, drugs can be introduced 
directly into the sampling site.  Microdialysis is often used for 
pharmacokinetic/pharmacodynamic (PK/PD) studies [51, 52].  A probe can be placed in 
the blood for analysis while, another probe can be placed in the tissue.   
 There are some drawbacks to microdialysis sampling.  One such drawback is the 
extraction efficiency of the membrane.  Since the probe never reaches an equilibrium 
with the surrounding tissue, the amount of the analyte that is recovered is always less 
than the in vivo concentration. This can be problematic when the analyte is in such low 
concentrations that the limit of detection for the analytical method is approached.  
Another drawback, depending on the system being studied, is the temporal resolution.  
Specifically in the brain, where release of neurotransmitters occur on a sub-second time 
scale, by sampling on a time scale of minutes, important information could be lost [53, 
54].  The issue with temporal resolution and extraction efficiency play off one another 
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since decreasing the flow rate through the membrane increases the extraction efficiency, 
but at the expense of temporal resolution.  However, temporal and spatial resolution as 
well as the advantages of using each animal as its own control is more advantageous than 
tissue homogenate, which is often used.   
 
1.5.5 Applications 
 Microdialysis is most often used for the study of brain neurochemistry.  These 
studies often include the analysis of major brain neurotransmitters, including amino acids 
[55-57], dopamine [58, 59], norepinephrine [60, 61], and serotonin [62, 63].  Studies in 
the brain have also looked at neuropeptides [64, 65].  Blood brain barrier permeability 
has been studied by systemic dosing of fluorescein and its subsequent detection in the 
brain after oxidative damage [66, 67].  Another area in which microdialysis has been 
useful is during behavioral studies.  Brain neurochemical data can be correlated with 
behavioral data to give a broader picture of the function of the brain in addiction [68, 69] 
and disease states such as Huntington’s and Alzheimer’s [70, 71].  Microdialysis has also 
been coupled with on-line detection schemes to decrease sample handling and use 
capillary electrophoresis microchips to increase temporal resolution [59, 72].  In addition 
to sampling in the brain, microdialysis has been used in various other tissues including 
the heart [73, 74], muscle [75], stomach [76, 77], intestines [78], skin [79, 80], liver [81, 
82], and eyes [83].   
 One area in which microdialysis has become especially prevalent is in 
pharmacokinetic studies.  Typical absorption, distribution, metabolism and excretion 
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(ADME) studies involve blood, urine, and tissue collection.  Taking serial blood draws 
and urine collections in small animals is troublesome and collecting tissue results in 
limited time points per animal.  Using microdialysis for blood collection is advantageous 
because no fluid is lost during collection, meaning more time points can be taken for each 
animal.  A drug can be dosed and its concentration can be monitored in the blood, urine, 
and peripheral tissues simultaneously [84, 85].  Pharmacokinetic data can also be 
correlated with pharmacodynamic changes as well [17, 52].  
 
1.6 Separations 
 While microdialysis sampling results in a rather clean sample, particularly the 
elimination of proteins, and decreases the need for time consuming sample cleanup when 
compared with tissue homogenate, an in vivo sample is complex.  The use of separation-
based techniques for the identification of analytes in a complex sample is one of the most 
important tools for analytical chemists.  Advances in both separation techniques and 
detection schemes have allowed for the detection of analytes in the small sample sizes 
from microdialysis.   
 
1.6.1 Liquid Chromatography 
1.6.1.1 Theory 
 Liquid chromatography (LC) has been in use since the 1960’s.  LC is the most 
widely used separation technique for non-volatile hydrophobic compounds in the liquid 
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phase.  The separation in LC is based upon the interaction of the analyte in the mobile 
phase (liquid) with the solid stationary phase.  Figure 1.5 shows a typical setup for liquid 
chromatography.  The mobile phase is kept in a reservoir where it is constantly purged 
with an inert gas to remove oxygen.  This is important for three reasons.  One, with 
certain detection schemes, mainly electrochemical detection, oxygen can be reduced and                                                                                    
its detection can interfere with the main analyte.  Second, a major problem for pump 
problems with liquid chromatography is air bubbles in the pump head; removing oxygen 
can reduce this problem.  Third, many neurotransmitters are oxidized in the presence of 
oxygen.  From the mobile phase reservoir, the mobile phase enters the pump where 
solvent is delivered, up to several thousand psi, to the column.  Between the pump and 
the column, the sample is introduced through the injector port.  Once the separation is 
complete, detection of the analyte is performed by the detector and the data are sent to a 
CPU where offline analysis is performed.   
 Separations can be performed using anywhere from one pump, to several.  When 
one pump and mobile phase is used, it is termed an isocratic separation.  This is the 
simplest separation.  However, when compounds have widely varying retention times, a 
gradient separation can be performed, where two or more pumps and mobile phases are 
used.  By using a gradient, late eluting compounds can have their partitioning diminished, 
and separation of compounds with widely varying chemical properties can be performed 
in the same run.   
 Retention of the analyte on the column is described by the capacity factor, k’, 
which describes the amount of time spent in the mobile phase relative to the stationary 
phase.  Equation 1.3 is for calculating the capacity factor, where tr is the retention time 
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for the analyte of interest and tm is the retention time for any unretained compounds.  
Figure 1.6 shows a chromatogram illustrating tr and tm.   
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Figure 1.5 Schematic of a typical HPLC system [86]. 
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(1.3)  
 
All compounds will spend equal time in the mobile phase; therefore, separation of 
multiple analytes in a matrix will depend upon the amount of time spent in the stationary 
phase.  The ability for the stationary phase to separate two analytes from one another is 
described by the selectivity, where k’1 and k’2 are the capacity factors for the two 
analytes. Selectivity (α) is assessed by equation 1.4. 
 
(1.4)    
 
Column efficiency (N) is described by equation 1.5, where t2 is the retention time and w 
is the peak width at the base.   
 
(1.5)    
 
The resolution between these two analytes is given by equation 1.6.  Each term in the 
equation describes a part of the separation process which leads to resolution between two 
analytes.  The first term (N) involves column efficiency, the larger the value for N the 
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more narrow the peaks.  The second term involves the selectivity (α) and how well one 
analyte is retained over another.  The third term involves the capacity factor, which 
describes the length of time an analyte is on the column.  The longer two analytes are on 
the column, the longer they have to be separated.  
 
(1.6)    
 
Column efficiency, N, can be used to calculate the number of theoretical plates, H.  The 
larger the value of H, the more efficient the column.  Equation 1.7 describes the 
theoretical plate height in terms of the efficiency, N, and column length, L. 
 
(1.7)   
 
Theoretical plate height can be related then to the Van Deemter equation (Equation 1.8), 
which describes how each type of band broadening determines the total plate height.   
 
(1.8)   
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A represents dispersion of the analyte due to Eddy Diffusion, or the multiple paths term.  
B is longitudinal diffusion, which is in the direction of flow.  C is the mobile phase 
transfer term, which is a kinetic term for the mobile phase in the stationary phase.  u 
represents the mobile phase linear velocity.  Diffusion perpendicular to the flow of 
mobile phase is necessary, because that is what provides the separation, however 
diffusion parallel to the flow is destructive.   
 Advances have allowed for the movement towards so-called “ultra” performance 
liquid chromatography (UPLC).  By decreasing particle size (<2µm), separations become 
more efficient and are performed over a shorter period of time.  The drive towards UPLC 
was due to the need for more high throughput methods, as well as the analysis of 
complex samples.  A study by Guillarme et al. showed that by moving from a 4.6 x 
150mm column with 5µm particle size to a 2.1 x 50mm column with a 1.7µm particle 
size, a sample of 12 compounds was separated in 1.6 minutes versus 27 minutes with the 
larger column [87].  While UPLC utilizes smaller particle sizes that result in higher back 
pressures, there is no fundamental difference between HPLC and UPLC.  UPLC takes 
advantage of the smaller particle sizes which decreases the Eddy Diffusion term in the 
Van Deemter equation as described above.   
 
1.6.1.2 Modes of Separation 
 There are several different modes of separation in liquid chromatography, 
including reverse phase, normal phase, ion exchange, and size exclusion.  The optimal 
mode of separation is determined based upon the analytes being separated and which 
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mode will allow for the best separation.  In reverse phase chromatography, the stationary 
phase is more hydrophobic than the mobile phase.  This is by far the most commonly 
used mode in separations for aqueous samples.  The stationary phase in a reverse phase 
system is silica based and the most common ligands are -C18 (octydecyl) and –C8 
(decyl).  These carbon chains can be chemically modified for better retention of certain 
analytes, such as polar endcapping of –C18 chains for better retention of polar 
compounds.  If the analytes of interest are very hydrophobic, they will spend more time 
in the hydrophobic stationary phase over the more polar mobile phase.  This problem can 
be remedied and thus separation time decreased by adding organic to the mobile phase.  
This is often why in a gradient separation the second mobile phase has a higher 
percentage of organic, to help elute hydrophobic compounds from the column.  When 
performing reverse phase chromatography, more hydrophilic compounds might be 
unretained and elute with the void volume.  If there is a mix of hydrophobic and ionic 
compounds, an ion pairing agent can be added.  One such example of an ion pairing agent 
is 1-octanesulfonic acid (SOS).  The charge on the SOS matches up with the charge on 
the analyte, this decreasing the overall charge on the analyte and allowing it to interact 
more with the stationary phase, removing it from the void volume.   
 Normal phase chromatography is another mode of separation.  In normal phase, 
the stationary phase is more polar than the mobile phase.  Often times in normal phase 
chromatography the mobile phase is 100% organic.  The stationary phase in normal phase 
systems are typically silica or alumina based. Silica phases can also be modified to make 
them more polar, for example by adding hydroxyl groups.   
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 Ion exchange chromatography makes use of an ionic stationary phase and is 
separated into cationic exchange and anionic exchange depending on the charge of the 
analyte of interest.  Analytes are separated based upon ionic interactions with the 
stationary phase.  The charge of the analytes can be altered by changing the pH of the 
mobile phase.   
 Size exclusion chromatography is used for large molecules, greater than around 
2,000 amu.  The analytes do not interact with the surface of the stationary phase, rather 
separation is determined by diffusion into the pores of the stationary phase.  Small 
analytes will diffuse into more pores on the stationary phase and thus will elute last, 
while large molecules that cannot fit into the pores will elute first.   
 
1.6.1.3 Modes of Detection 
 The most commonly used detector for LC separations is a UV/Vis absorbance 
detector.  Many compounds absorb UV radiation and a signal is produced.  Absorbance 
(A) is given by equation 1.9, where ε is the molar absorptivity constant, b is the path 
length of the detector cell, and c is the concentration.   
 
(1.9)   
 
The detector can either be set up for a single wavelength using a monochromator or for 
multiple wavelengths using a photo-diode array.  A monochromator selects one 
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wavelength (typically near maximum absorptivity) and provides a sharp strong light 
which will provide the best limits of detection.  A diode array detector allows for 
detection of several different wavelengths at one time and is useful for method 
development or when several analytes are detected with different absorption maximums.  
The biggest problem with UV/Vis detection is that it is not very selective.  In addition to 
its relatively poor limits of detection, UV/Vis is a ratio measurement and one is trying to 
measure a small change in a big signal.   
 A mode of detection with better limits of detection is fluorescence.  Fluorescence 
occurs when the molecule absorbs a photon at one wavelength and emits the photon at a 
longer wavelength.  The big advantage of fluorescence over UV/Vis is that fluorescence 
is a direct measurement.  While almost all organic molecules absorb UV light, not every 
molecule fluoresces.  The biggest disadvantage to fluorescence detection is that 
compounds not natively fluorescent must be derivatized, which adds another step to the 
analysis.   
 Another detection mode with excellent limits of detection is electrochemical (or 
amperometric) detection.  Electrochemical detection is used when the analytes of interest 
have moeties that are easily oxidized or reduced.  Electrodes can be made of many 
different materials, the most common being glassy carbon, but also carbon paste, gold, 
gold/mercury amalgam, and platinum.  The selectivity of electrochemical detection is 
quite good as the applied potential can be changed to maximize the oxidation/reduction 
of the analyte of interest while remaining below the oxidation/reduction potentials of 
other compounds in the matrix.  The drawback to electrochemical detection is fouling of 
the electrode surface resulting in the need to polish the electrode on a regular basis.   
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 Recently the most widely used detection scheme is mass spectrometry.  Mass 
spectrometry has been especially useful when coupled with LC, but has been used for 
decades coupled to gas chromatography.  When coupled to LC, mass spectrometry 
detects analytes based on their mass to charge ratio.  One primary problem with using 
mass spectrometry in conjunction with microdialysis samples is the salt content in aCSF 
and Ringers solution.  Coupling microdialysis with liquid chromatography mass 
spectrometry has been an issue [88, 89], as the high salt content of microdialysis samples 
causes signal suppression and decreases ionization efficiency [90].  Since analytes must 
be in the gas phase for detection, increasing the ionic strength of the solution increases 
the boiling point and thus results in a significant loss of sample due to poor ionization.  
 
1.7 Overview of Research 
 The goal of this research was to develop a model for local dosing of 3-
Mercaptopropionic acid through an intracerebral microdialysis probe.  Microdialysis with 
an intracerebral microdialysis probe coupled with an internal working electrode for 
electrophysiological recording of seizure activity at the site of 3-MPA administration was 
used.  The purpose of this research was to develop a seizure model to induce seizures in a 
specific brain region to model the focal seizures seen in many clinical patients.  The 
microdialysis samples were analyzed for 3-MPA delivered to the brain, as well as to 
monitor changes in amino acid and catecholamine neurotransmitters and their 
metabolites.   
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 Chapter three discusses the changes seen in amino acids and catecholamine 
neurotransmitter levels in three brain regions: the striatum, hippocampus, and locus 
coeruleus, upon administration of 10mM 3-MPA through the microdialysis probe.  3-
MPA was administered through one probe while samples were collected in the other two 
probes concurrently.  This allowed for a determination of the local dosing model of 3-
MPA, where administering 3-MPA through one probe would not effect the brain region 
surrounding the other two probes.  This also allowed for the investigation of neuronal 
circuitry where changes can be seen in distant brain regions if neurons project from the 
region where 3-MPA is administered to a distant brain region where another probe is 
placed. The delivery of 3-MPA to the brain was also evaluated.  The neurochemical 
changes as well as 3-MPA delivery were correlated to changes in ECoG activity. 
 Chapter four discusses a multiple dosing approach for 3-MPA in the 
hippocampus.  3-MPA administration was divided into two equal periods and the changes 
in amino acids and catecholamine neurotransmitters were monitored to investigate 
whether neurons lose their plasticity or undergo protective mechanisms in response to 
subsequent seizure events.   
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Chapter 2 
Methods 
2.1 Introduction 
2.1.1 Background and Significance 
 Previous research in our laboratory involved a 
pharmacokinetic/pharmacodynamic study of a chemically-induced seizure model with 3-
MPA in rats [1].  A steady-state model for 3-MPA dosing was developed where a 60 
mg/kg min-1 bolus dose was followed by a constant intravenous (i.v.) infusion of 50 
mg/kg of 3-MPA for 50 minutes.  The concentrations of 3-MPA were measured in the 
blood as well as the striatum and hippocampus.  The 3-MPA concentrations in the brain 
can be seen in Figure 2.1.  Steady-state concentrations of 3-MPA were achieved in the 
brain and the pharmacokinetics of 3-MPA in the blood and brain were studied.  This was 
the first known study of the pharmacokinetics of 3-MPA in a chemically-induced seizure  
model.  By achieving steady-state concentrations of 3-MPA, that variable was held 
constant when studying the neurochemical changes in the striatum and hippocampus.  As 
expected, 3-MPA inhibited the conversion of glutamic acid to γ-hydroxybutyric acid in 
vivo, resulting in an increase in glutamic acid and a decrease in γ-hydroxybutyric acid. 
These changes can be seen in both the striatum and hippocampus in Figure 2.2.  In 
addition to measuring the concentrations of 3-MPA and neurochemical changes in the 
brain, ECoG recordings were made.  Thus, seizure number, intensity, and duration were 
correlated 3-MPA concentrations and neurochemical changes.  Table 2.1 outlines the data 
obtained from the ECoG recordings.  
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(A)	  
(B)	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Average brain 3-MPA concentration-time profiles in the striatum (A) and 
hippocampus (B) following constant infusion dose of 3-MPA.  3-MPA was dosed at time 
t=0 minutes.  Area in the box denotes steady-state 3-MPA concentrations.  The infusion 
was discontinued at the arrow.   n=16 striatum, n=3 hippocampus [1]. 
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Figure 2.2 Changes in Glu and GABA in the striatum (A) and hippocampus (B) 
following systemic dosing of 3-MPA with the constant infusion dosing 
(60mg/kg bolus + 50mg/kg constant infusion for 50 minutes).  (A, n=12 rats), 
(B, n=3 rats). [*=p<0.1, **=p<0.05, ***=p<0.01] [1]. 
 
(A) 
(B) 
	   45	  
Table 2.1  ECoG data for constant infusion dosing in the striatum [1].  
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 While this constant infusion model was an important first step in the development 
of 3-MPA epileptic seizure model, was not as clinically relevant.  Research has shown 
that 70% of adult onset epilepsy patients present with partial (focal) seizures [2].  This 
means that the seizures are localized in a specific brain region.  3-MPA in this constant 
infusion model is dosed to the brain globally, and thus its physiologic and neurochemical 
changes are on a global scale as well.  The purpose of these studies was to develop a 
model where 3-MPA is dosed to a specific brain region and the physiological and 
neurochemical changes could be monitored in a site specific manner while not disturbing 
the neurochemical balance in the brain as whole.  A comparison was made between the 
local dosing and the constant infusion model, as well as a comparison between awake and 
anesthetized animals in various brain regions.   
 
2.1.2 Amino acid neurotransmitters 
 The structures of the main amino acid neurotransmitters of interest in this research 
are shown in Figure 2.3.  While aspartic acid, arginine, and alanine will be monitored in 
microdialysis samples, they are not of extra importance since 3-MPA works on the 
glutamic acid/γ-hydroxybutyric acid system.  Glutamic acid is the main excitatory 
neurotransmitter in the brain; γ-hydroxybutyric acid is the major inhibitory amino acid in 
the brain.  Disruption of this system by administration of 3-MPA, resulting in an increase 
in glutamic acid and a decrease in γ-hydroxybutyric acid, results in seizures.  The 
Glutamic acid/ γ-hydroxybutyric acid ratio will aid in the understanding of seizure 
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development in the 3-MPA system.  The metabolic synthesis of glutamic acid and γ-
hydroxybutyric acid can be seen in Figure 2.4. 
 
2.1.3 Catecholamine neurotransmitters and their metabolites 
The catecholamine neurotransmitters of interest are in Figure 2.5.  Figures 2.6 and 
2.7 show the biosynthesis and metabolism of the neurotransmitters dopamine (DA), 
norepinephrine (NE), and serotonin (5-HT) as well as their metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-
hydroxyindoleacetic acid (5-HIAA).  
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Aspartic	  Acid	  (Asp)	  
pKa	  ~	  2.28	  (most	  acidic)	  
pKa	  ~	  9.95	  (most	  basic)	  
Glutamic	  acid	  (Glu)	  
pKa	  ~	  2.17	  (most	  
acidic)	  
pKa	  ~	  9.76	  (most	  
basic)	  
Arginine	  (Arg)	  
pKa	  ~	  2.49	  (most	  acidic)	  
pKa	  ~	  13.58	  (most	  basic)	  
Alanine	  (Ala)	  
pKa	  ~	  2.31	  (most	  acidic)	  
pKa	  ~	  9.61	  (most	  basic)	  
γ-­‐Hydroxybutyric	  acid	  
pKa	  ~	  4.44	  (most	  acidic)	  
pKa	  ~	  11.24	  (most	  basic)	  
Figure 2.3 Structures of the amino acid neurotransmitters of interest.  pKa values 
were obtained from SciFinder© Scholar 2007. 
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Figure 2.4 Metabolic synthesis and breakdown of glutamic acid and γ-
hydroxybutyric acid [1]. 
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Figure 2.5 Catecholamine neurotransmitters of interest. pKa values were obtained 
from SciFinder Scholar 2007. 
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Figure 2.6 Biosynthesis and metabolism of catecholamine neurotransmitters [1]. 
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Figure 2.7 Metabolism of Tryptophan leads to the neurotransmitter 5-
Hydroxytryptamine (serotonin) [1]. 
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2.1.4 Methods for the determination of neurotransmitters and their metabolites in 
biological  samples. 
Since the biological samples containing neurotransmitters are often complex, 
detection is coupled with a separation technique.  The two separation techniques used for 
detection of neurotransmitters are liquid chromatography and capillary electrophoresis.  
With these two separation techniques, fluorescence and electrochemical detection are 
most widely used.  With an LC separation, fluorescence detection of amino acid 
transmitters is most often used (see section 2.2.3) [3, 4].  If the neurotransmitters are 
electroactive, they can be detected by LC coupled with electrochemical detection [5, 6].  
When sample size is a consideration, especially with microdialysis samples, capillary 
electrophoresis is a good separation scheme.  As with LC, neurotransmitters are often 
detected by fluorescence in CE [7, 8] as well as electrochemical detection [9, 10].  Other 
techniques include biosensors, such as those for glutamate [11], and cyclic voltammetry 
for dopamine [12, 13]. 
 
2.1.5 Mechanisms of action of 3-mercaptopropionic acid 
 The mechanism of action of 3-MPA has been well studied.  3-MPA is a 
competitive inhibitor of the enzyme glutamic acid decarboxylase (GAD) which is 
responsible for converting glutamic acid to γ-aminobutyric acid [14-17].  This results in 
an increase in glutamic acid and a decrease in γ-aminobutyric acid [18-22]. 
 3-MPA first produces myoclonic seizures, but over time, tonic-clonic seizures 
develop [23].  Myoclonic seizures are very brief, 2-3 seconds in duration, and are 
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characterized by twitches or jerks in the muscle.  They usually involve just the forelimbs, 
nose, and whiskers.  Tonic-clonic seizures are more violent and typically last for several 
minutes.  These types of seizures usually involve the entire body.   
 
2.1.6 Current uses for 3-mercaptopropionic acid 
 3-MPA has been used as a chemical convulsant for quite some time. 3-MPA has 
been used to study the pharmacokinetics of the anti-epileptic drug  Phenobarbital [24, 
25].  Neuronal lesions caused by administration of 3-MPA have been studied by 
O’Connell [26] and Towfighi [27].  This allows for the study of localized brain damage 
due to status epilepticus.   
 While 3-MPA has widespread use as a convulsant, it has many other analytical 
uses as well.  3-MPA has been used to form a gold monolayer for the detection of 
catechin, a plant derived polyphenolic antioxidant [28].  Additionally, it has been used as 
a tag on gold nanoparticles for Hg+2 detection as well as to form alkanethiol monolayers 
for the detection of the superoxide radical by immobilized cytochrome c [29, 30]. 
 
2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
 Monobasic sodium phosphate, dibasic sodium phosphate, sodium chloride, 
potassium chloride, magnesium chloride, calcium chloride, disodium ethylenediamine 
tetra acetate (Na2EDTA), 85% o-phosphoric acid, and 0.3 µm alumina powder were 
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purchased from Fisher Scientific (Pittsburgh, PA).  L-aspartic acid, L-glutamic acid, L-
arginine, L-alanine, L-gammabutyric acid, DL-2-aminoadipic acid, 3-mercaptopropionic 
acid, ammonium acetate, 1-octanesulfonic acid, HPLC grade methanol, and HPLC grade 
tetrahydrofuran were purchased from Sigma-Aldrich (St. Louis, MO). Triple distilled 
mercury was obtained from Bethlehem Apparatus Company (Hellertown, PA).  Ketamine 
HCl was obtained from Fort Dodge Animal Health (Fort Dodge, IA).  Xylazine was 
obtained from Lloyd Laboratories (Shenandoah, IA).  Acepromazine was obtained from 
Boehringer Ingelheim Vetmedica, Inc. (St. Joesph, MO). All solutions in water were 
prepared with 18.2 MΩ distilled, deionized water (Labconco, Kansas City, MO).   
 
2.2.2 Microdialysis Sample Considerations 
 An appropriate amount of recovery time is needed after microdialysis probe 
implantation for neurotransmitters to return to basal levels.  The trauma induced during 
microdialysis probe implantation has been well documented.  Gliosis occurs from local 
brain tissue being disturbed during implantation [31, 32].  There is an excess of 
neurotransmitter release into the extracellular space, as well as increased glucose 
metabolism and a decrease in blood flow [32].   
 One key in microdialysis experiments is to maximize the temporal resolution of 
your sampling so that trends in the extracellular events being explored can be identified.  
In the experiments described in this thesis, five minute sampling intervals were used.  
This was the minimum sampling duration that allowed for enough sample to be collected 
for analysis.  An artificial cerebral spinal fluid (aCSF) solution (145mM NaCl, 2.7mM 
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KCl, 1.0mM MgCl2, 1.2mM CaCl2, 0.45mM NaH2PO4, 2.33mM Na2HPO4) was used 
that closely mimics the cerebral spinal fluid found in rats, to minimize loss of ions during 
sampling.  aCSF was perfused through the probe at 1.0 µL/min and collected in an outlet 
vial.  During the five minute sampling period, 5 µL of sample was collected.  2.5 µL was 
used for 3-MPA analysis, while 2.5 µL was reserved for amino acid analysis.    
 An internal standard in 0.1M perchloric acid was spiked into the microdialysis 
sample to prevent autooxidation of any compounds in the aCSF sample matrix prior to 
analysis.  Perchloric acid has been shown to increase the stability of these samples [33, 
34].  If the microdialysis samples could not be analyzed immediately, the samples were 
flash frozen in liquid nitrogen and stored in a -20°C laboratory freezer to maintain 
stability.   
 
2.2.3 Sample Derivitization Scheme 
 Since many amino acid neurotransmitters are not natively fluorescent (for 
example glutamate and GABA), they must be derivatized prior to separation by either CE 
or LC and detection.  The two most commonly used reagents are o-phthaldehyde (OPA) 
and  naphthalene-2,3-dicarboxyaldehyde (NDA). OPA selectively reacts with primary 
amines in the presence of an alkyl thiol (usually β-mercaptoethanol (βME)) to form 1-
alkylthio-2-alkyl-substituted isoindoles, as first shown by Simons and Johnson [35].  
OPA has been used extensively for the analysis of amino acids by both LC and CE [36, 
37].  OPA is non-fluorescent prior to the reaction, thus making it an attractive reagent.  
The downside to OPA as a derivatization reagent is its poor stability.  Jacobs et. al. 
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showed that the OPA adduct forms within a minute, but then quickly degrades to non-
fluorescent by-products [38].  This fact limits the use of OPA for pre-column 
derivatization schemes.   
Naphthalene-2,3-dicarboxyaldehyde is the other most commonly used 
derivatization reagent, which also reacts selectively with primary amines.  NDA was 
developed by De Montigny et. al. and reacts with a nucleophile, the cyanide ion (CN-), to 
form N-substituted-1-cyanobenz[f]isoindole adducts [39].  The N-substituted-1- 
cyanobenz[f]isoindole adducts are also significantly more stable than those formed with 
OPA, being stable for 12 hours [39].  NDA adducts with CN- as the nucleophile have an 
excitation at 440 nm and an emission at 490 nm, with a quantum efficiency of 0.54 in 
60% acetonitrile [39].  Like OPA, NDA/CN has been widely used for the detection of 
amino acids with both LC and CE [40-42].  The NDA/CN reaction scheme can be seen in 
Figure 2.8.   
 For the analysis of amino acids in microdialysis samples, 2.5 µL of microdialysate 
was spiked with 1.5 µL of the internal standard (DL-2-aminoadipic acid ), 1.0 µL of 500 
mM borate : 87 mM CN- (100 : 20 v:v), and 1.0 µL of 3mM NDA in an acetonitrile: 
water solution (50:50, v:v).  Of that 6.0 µL of sample, 5.0 µL was injected for analysis. 
The reaction was allowed to take place for 30 minutes at room temperature to allow for 
complete derivitization of the samples.  Figure 2.9 shows the change in peak height as a 
function of reaction time for NDA and the amino acid containing samples.  
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Figure 2.8 The reaction of NDA/CN- with primary amines (RNH2). 
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Figure 2.9 Peak heights for NDA adducts of amino acids as a function of 
reaction time.  
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2.2.4 Instrumentation 
2.2.4.1 3-mercaptopropionic acid and catecholamine neurotransmitters 
 A liquid chromatographic system with electrochemical detection was used for the 
detection of 3-mercaptopropionic acid and the catecholamines in microdialysis samples.  
A Shimadzu LC-20AD pump and Rheodyne 9725i PEEK sample injector were connected 
to an Agilent ZORBAX 3.5µm SB-C18 column (1.0 x 50mm, Agilent Technologies, 
Santa Clara, CA) with a Phenomenex C18 guard cartridge.  The mobile phase was 
adapted from Stenken et. al. and consisted of a phosphate buffer with methanol (90:10, 
v:v) [43].  Specifically, 125mM NaH2PO4, 20.0mM Na2EDTA, and 0.75mM 1-
octanesulfonic acid was pH adjusted to 3.5 with 85% o-phosphoric acid.  
Electrochemical detection was performed using a thin layer dual glassy carbon 
Au/Hg amalgam electrode.  Preparation and use of the electrode is described in Allison 
and Shoup [44].  Briefly, a 3mm glassy carbon/Au electrode embedded in a PEEK block 
(Bioanalytical Systems, West Lafayette, IN) was polished with 15 µm, 6 µm, 3 µm, 1 µm 
diamond polish (Bioanalytical Systems, West Lafayette, IN) followed by 0.3 µm alumina 
powder.  Following polishing, the electrode was rinsed with methanol and water.  Triple 
distilled mercury was placed over the gold electrode and allowed to rest for 5 minutes.  
Excess mercury was then removed with the edge of a credit card and it was allowed to set 
overnight.  Once the almalgamation process was complete, the electrode was placed into 
the electrochemical flow cell and was allowed to equilibrate with the mobile phase and 
dissipate charging current.  Figure 2.10 below shows a schematic of the parallel dual 
electrode setup. 
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Figure 2.10 Dual Au/Hg + Glassy carbon working electrode in parallel 
configuration.  Electrochemical operating conditions are identical to those 
described in 2.2.4.1 [1]. 
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Detection of 3-MPA was done at +100mV versus a Ag/AgCl reference electrode 
based on a hydrodynamic voltammogram (HDV) [1].  The potential was set using a LC-
4C potentiostat (Bioanalytical Systems, West Lafayette, IN).  Detection of 3-MPA was 
done indirectly by the oxidation of mercury as the thiol passes over the electrode surface.  
2.5 µL of microdialysate was injected for the analysis of 3-MPA.  The electrochemical 
equation can be seen in Equation 2.1. 
 
(2.1) 
 
The data was collected at 10 Hz and processed using a Chrom&Spec Chromatography 
Data System (Ampersand International, Beachwood, OH).  The structure of 3-MPA and 
detection scheme of 3-MPA can be seen in Figure 2.11 below.   
  Detection of the catecholamines, dopamine (DA) and norepinephrine (NE), and 
their metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 
and 5-hydroxyindoleacetic acid (5-HIAA), was performed at +750mV at the glassy 
carbon electrode.  A typical chromatogram for detection of the catecholamine 
neurotransmitters can be seen in Figure 2.12 below. 
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Figure	  2.11	  Typical	  Chromatogram	  of	  3-­‐MPA.	  (A)	  Structure	  of	  3-­‐MPA.	  (B)	  LC-­‐EC	  detection	  of	  3-­‐
MPA	  at	  +100mV	  versus	  Ag/AgCl	  reference	  electrode	  [1].	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Figure 2.12 Typical LC-EC chromatogram from brain 
microdialysate. 
	   65	  
 2.2.4.2 Amino acid neurotransmitters 
 A liquid chromatographic system with fluorescence detection was used for the 
analysis of the amino acid neurotransmitters in microdialysis samples. Two Shimadzu 
LC-10ADvp pumps, a Shimadzu 100 µL mixer and Rheodyne 9725i PEEK sample 
injector were connected to a Phenomenex Synergi 4µm Hydro-RP column (150 x 2.0mm, 
Phenomenex, Torrance, CA) with a Phenomenex C18 guard cartridge.  The binary 
gradient was controlled by a Shimadzu SCL-10vp System Controller.  Mobile Phase A 
consisted of 50mM ammonium acetate pH adjusted to 6.8 with glacial acetic acid. 5% 
Tetrahydrofuran (THF) was added making the final concentration 95% acetate : 5% THF 
(v:v).  Mobile phase B consisted of 100% methanol.  The method was adapted from Shah 
et. al. [45]. A Shimadzu 10AXL fluorescence detector was operated at an excitation 
wavelength of 442nm and an emission wavelength of 490nm [46].  A typical 
chromatogram for the detection of the amino acids can be seen below is Figure 2.13. 
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Figure 2.13 Typical LC-FL chromatogram from brain microdialysate. 
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2.2.5 Surgical Procedures 
2.2.5.1 Animal and Instrumentation Preparation 
 Male Wistar Rats (Charles River, Charles River Laboratories, Wilmington, MA) 
weighing between 300-450g were used.  The animals were kept on a 12 hour light/dark 
cycle and had free access to food and water prior to surgery. The research described 
follows the principles stated in the Guide for the Care and Use of Laboratory Animals, 
NIH publication 86-23, 1996 edition.  Experimental animals were initially anesthetized 
by inhalation of isoflurane followed by an i.p. injection of a ketamine (67.5 mg/kg)/ 
xylazine (3.4 mg/kg)/ acepromazine (0.67 mg/kg) mixture.  The animals were closely 
monitored during all procedures.  Booster doses of one-fourth or one-half of the original 
dose of ketamine was used as needed to maintain adequate anesthesia.  The animal's body 
temperature was kept at 37°C using a Homeothermic Blanket Control Unit (Harvard 
Apparatus, Holliston, MA).  The incision sites were prepared by shaving away as much 
hair as possible and then disinfecting with three alternate scrubs each of Prodine Scrub 
(0.75% aqueous iodine, Phoenix Pharmaceutical, Inc.  St. Joseph, MO.  USA) and a 70% 
(v:v) solution of aqueous ethanol.  The incisions were closed with sutures or surgical 
staples.  All solutions injected into the animal were filtered using a disposable 0.2 µm 
nylon syringe filter (Acrodisc filters, Fisher Scientific).  Surgical tools, drapes, sutures, 
cannulas, and rinsing water used for survival procedures were sterilized by ethylene 
oxide. 
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2.2.5.2 Microdialysis Brain Probe Implantation 
Rats were anesthetized as described above.  The hair on the top of the rat skull 
was shaved and the skin and scalp cleansed via betadine/alcohol rub.  The animal was 
then securely positioned in a stereotaxic apparatus with incisor bar set at 3.3 mm from the 
interaural saggital suture.  Adventitious tissue covering the skull was removed using 
cotton swabs.  Two 1 mm diameter holes were drilled approximately 2 mm anterior and 
posterior to the insertion site of the guide cannula through the skull.  Two stainless steel 
anchor screws (1 mm diameter, 2 mm length) were inserted into these holes.  Next, a 1 
mm diameter hole was drilled through the skull at the insertion site and an intracerebral 
guide cannula (CMA Microdialysis Inc., North Chelmsford, MA) was lowered into the 
cerebral cortex using a micromanipulator attached to the stereotaxic apparatus.  The 
guide cannula was positioned 2 mm above the hippocampus, 4mm above the striatum, 
and 0.5mm above the locus coeruleus, then affixed to the skull with dental cement. The 
dummy probe in the guide cannula was then replaced with an Applied Neuroscience 
(Applied Neuroscience, London, UK) microdialysis probe with an internal Ag/AgCl 
working electrode. A 4mm Applied Neuroscience microdialysis probe with a 
Polyarylethersulphone (PAES) membrane was used in the striatum with coordinates: 
posterior +0.2 mm, lateral +3.2 mm, ventral -7.5 mm, a 2mm probe was used in the 
hippocampus (CA1) with the coordinates: anterior -3.3 mm, lateral +1.7 mm, ventral -3.7 
mm, and a 0.5mm probe was used in the locus coeruleus with the coordinates: anterior -
9.8mm, lateral +1.2mm, ventral -7.2mm.   
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2.2.6 ECoG recording 
 ECoG recordings were made using a SynAmps RT system (Compumedics 
Neuroscan, Charlotte, NC).  Microdialysis probes with an internal Ag/AgCl working 
electrode were connected to the headbox and Ag/AgCl wires were placed under the scalp 
as the reference and ground.  Data was collected using SCAN software.  A 20000Hz 
sampling rate was reduced to a 200Hz sampling rate by computing mean values of the 
signals within adjacent time windows with the volume 100 samples.  Seizures were 
detected based upon their score from the algorithm output. 
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Chapter 3 
 
3-MPA Local Dosing in the striatum, hippocampus, and locus coeruleus 
 
3.1 Introduction 
3.1.1 Background and Significance 
The major reasons for modifying the existing method for systemic dosing of 3-
MPA [1, 2] were to achieve true local administration and minimal systemic toxicity of 3-
MPA to generate seizures in a defined local brain region.  This was important since many 
clinical cases present with local seizures, defined to a brain region [3].  One way to 
determine whether local administration of 3-MPA is being achieved is to place 
microdialysis probes in different brain regions and collect samples while dosing 3-MPA 
through the probe in another region.  The circuitry of the brain is quite complex.  The 
brain is such a heterogeneous tissue with neuronal projections between many regions 
reaching far and wide.  The expectations are that concentrations of amino acids and 
catecholamine neurotransmitters will remain at basal levels in the surround tissue, unless 
the region where 3-MPA is being administered has afferent or efferent pathways 
connecting it with the region where a control probe is placed.  Afferent pathways carry 
nerve impulses toward the central nervous system (CNS), while efferent pathways carry 
nerve impulses away from the CNS.  In these sets of experiments, three probes were 
placed in the brain, in the striatum (putamen), the hippocampus (CA1), and the locus 
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coeruleus and samples were collected simultaneously in all three probes while 3-MPA 
was administered through only one probe, to see if excitation in one region is transmitted 
to another. 
 
3.1.2 Striatum 
The striatum is one of four regions making up the basal ganglia, as can be seen in 
Figure 3.1.  The striatum can be broken up into two regions, the caudate and the putamen.  
In rodents the caudate and the putamen are one single structure, but they are divided by 
an internal capsule in carnivores and primates [4].  The other three regions in the basal 
ganglia are the subthalmic nucleus, globus pallidus (including the internal and external 
segments), and the substantia nigra (composing both the pars compacta and pars 
reticulate). The putamen region of the striatum contains substantial neurons which release 
both glutamate and GABA, making this region a good choice for study of the 3-MPA 
model [5].  Widely studied, Figure 3.2 shows a schematic of circuitry within the basal 
ganglia.  Studies have shown the connections between regions of the basal ganglia and 
other reaches of the brain.  Carpenter et al. demonstrated, using horseradish peroxidase 
and isotopically labeled amino acids, that the subthalmic nucleus has connections with 
the globus pallidus pars external within the basal ganglia, but there were no connections 
with the striatum or substantia nigra [6].  Research has shown that there are three major 
types of neurons in the striatum: medium spiny neurons, large aspiny neurons, and 
medium aspiny neurons [4, 7-9].  95% of the striatum consists of medium spiny neurons, 
which project to the substantia nigra and the globus pallidus (both internal and external) 
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[4, 9].  The striatum receives excitatory inputs from the substantial part of the cortex with 
the exception of primary auditory and visual cortex [4, 10].  Importantly, for this research 
project, these inputs from the cortex utilize glutamate as their neurotransmitter [11, 12].  
Additional inputs via medium spiny neurons project in the form of glutamate from the 
centromedian and parafascicular nuclei of the thalamus [13, 14], adjacent medium spiny 
neurons project GABA from within the striatum [15], and dopamine from the substantia 
nigra pars compacta [6].  There are no indications of projections either from the striatum 
to the hippocampus (CA1) and locus coruleus or from the hippocampus or locus 
coeruleus to the striatum.  Therefore, administering 3-MPA into the striatum probe 
should not result in changes in amino acids and catecholamine neurotransmitters in the 
other brain regions.  The same can be said when dosing in either the hippocampus or 
locus coeruleus and collecting in the striatum.   
 
3.1.3 Hippocampus 
The hippocampus is part of the cerebral hemisphere and plays an important role in 
memory and learning.  The hippocampus is one of the most studied brain regions in 
epilepsy, due to its ability to be easily excited, in addition to evident tissue damage in the 
hippocampus following temporal lobe epilepsy [16-18]. Seizures in the hippocampus are 
better understood than any other brain region.  Seizures in the hippocampus most closely 
resemble human limbic and temporal lobe epilepsy, which comprises 40% of all human 
cases, and provides the reason this region is so well studied [19, 20].  There are three 
major pathways in the hippocampus which have been detailed by Andersen et al.: the 
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preforant pathway extends from the entorhinal cortex to the granule cells of the dentate 
gyrus, the mossy fiber pathway, which consists of the axons on the granule cells, extends 
to the CA3 pyramidal cells, and the Schaffer collateral pathway, which projects from the 
CA3 to the CA1 neurons [21, 22].  This can be seen in Figure 3.3.  Output from the 
hippocampus stretches to the prefrontal cortex and lateral septal area of the hypothalamus 
[23].  Inputs containing serotonin, norepinephrine, and dopamine are received from the 
nucleus reuniens of the thalamus [23].  GABAergic inputs also come from the medial 
sepatal area to all of the hippocampus [23].  Based upon these biochemical processes, 
there is no expectation for amino acids and catecholamine neurotransmitters to deviate 
from basal levels while dosing in the striatum or the locus coeruleus.  Additionally, when 
dosing in the hippocampus, there should not be any changes in either the striatum or the 
locus coeruleus.   
 
3.1.4 locus coeruleus 
The locus coeruleus (LC) is the main synthesis site of norepinephrine (NE) in the 
brain [24].  Studies have shown the norepinephrine content in the LC to be between 15 
and 53 ng/mg protein [25, 26].  Norepinephrine has been shown to be anti-epileptic [27, 
28].  This has been supported by the fact that NE has resulted in a delayed onset of 
amygdala kindling [29] and depletion of NE has resulted in shorter seizure onset time 
[30]. Projections from the locus coeruleus stretch to almost every region of the brain, 
with the exception of the striatum.  Regions innervated include the amgydala, thalamus, 
hippocampus, neocortex, pallidum, and the cerebellum [31-33].  Inputs to the locus 
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coeruleus are received from the central nucleus of the amygdala as well as the frontal 
cortex [34].  Figure 3.4 shows the inputs and outputs of the locus coeruleus.  The study of 
the locus coeruleus is interesting not just because of the role of norepinephrine in this 
region and its effect on the rest of the brain, but also due to the ability to see the effect of 
projections from this region.  While dosing in the locus coeruleus, no changes should be 
seen in the striatum; however changes should be seen in the hippocampus while dosing in 
the locus coeruleus, due to the projections within these two regions. 
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Figure 3.1 Coronal slice showing the basal ganglia 
components, including the putamen, where probes are placed 
in these experiments [22]. 
	   81	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Circuitry of the basal ganglia.  Excitatory neurons are in red, 
inhibitory neurons are in green, and excitatory/inhibitory circuits are in red and 
green.  Substantia nigra pars compacta (SNpc); globus pallidus pars externa 
(GPe); globus pallidus pars interna (GPi); intralaminar thalamic nucleus (IL); 
mid-brain  extrapyramidal area (MEA); superior colliculus (SC); substantia 
nigra pars reticulata (SNpr); subthalmic nucleus (STN) [4].  
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Figure 3.3 Pathways within the hippocampus.  Probes in 
these experiments are placed in the CA1 region [22]. 
	   83	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Projections into and from the locus coeruleus. Locus coeruleus (LC); 
hippocampus (Hipp); thalamus (Thal); olfactory bulb (OB); piriform cortex (PCx); 
neocortex (Cx); frontal cortex (FCx); paragigantocellularis brainstem nucleus (PGi); 
amgdala central nucleus (CeA); basolateral nucleus of the amgdala (BLA) [34]. 
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3.1.5 Neuronal projections 
 While microdialysis has been used in the past to determine the underlying 
neuronal projections within the brain [35-37], these studies were usually done using 
radiolabeled substrates and neurotransmitters [6, 38].  By using a radiolabeled 
neurotransmitter, one can follow the efferent pathways by monitoring the radiolabeled 
neurotransmitter in brain regions where projections are made.  One of the disadvantages 
to using microdialysis for these studies is that you cannot determine if neurotransmitter 
release in one region is of the same origin as what was released in another region.  Also, 
the time scale for these projections, on the order of milliseconds, is overshadowed by the 
longer sampling rate.   
 
3.1.6 Experimental 
 In these sets of experiments for the anesthetized rats, three probes were be placed 
in the brain, one in each of the three brain regions: striatum (putamen), hippocampus 
(CA1), and the locus coeruleus. Following probe implantation the rat was allowed to 
recover, while maintaining anesthesia, while aCSF was perfused through the probe (1.0 
µl/min) for four hours.  This was to allow time for the amino acids and catecholamine 
neurotransmitters to return to basal levels.  Following the four hour recover period, six 
background samples were collected every ten minutes.  Following background collection, 
10mM 3-MPA prepared in artificial cerebral spinal fluid (aCSF), was perfused through 
one of the probes for 50 minutes, while aCSF was perfused through the other two probes.  
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Following the 50 minutes of 3-MPA administration, the 3-MPA perfusion was terminated 
and aCSF was perfused through that probe the remaining 70 minutes of the experiment.  
During these two hours samples were collected every 5 minutes. A three probe approach 
was not implemented in the awake animal experiments, thus only one probe was 
implanted. During the awake animal experiments the rats were allowed to come out from 
under anesthesia and recover for 24 hours. Following these 24 hours, background and 
dosing samples were collected in the same fashion as for the anesthetized animals.  
 
3.2 Results and Discussion 
3.2.1 3-MPA delivery in the striatum, hippocampus, and locus coeruleus 
 Multiple 10mM 3-MPA standards were injected on the LC-EC system (Method 
described in 2.2.4.1) and averaged to obtain the value for a 10mM 3-MPA standard.  
Dialysate samples were injected and the amount of 3-MPA delivered to the brain (in 
µg/min) was determined based on the calculated extraction efficiency (EED) of 3-MPA.  
Extraction efficiency of 3-MPA was calculated using equation 3.1. 
 
(3.1)     
 
The amount of 3-MPA delivered to the brain was calculated by subtracting the amount of 
3-MPA in the dialysate from the perfusate and then converted to mass per unit time 
(µg/min) using the density of 3-MPA and flow rate of the syringe pump.  Figures 3.5 and 
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3.6 show the delivery of 10mM 3-MPA in the striatum and hippocampus of both 
anesthetized and awake rats.  Figure 3.7 shows the delivery of 10mM 3-MPA in the locus 
coeruleus of anesthetized rats.   
 Steady-state delivery of 3-MPA is reached in all rats.  This steady-state delivery is 
consistent across all three brain regions and in both awake and anesthetized rats.  This 
steady-state delivery of 3-MPA is advantageous, similar to the steady-state systemic 
dosing of 3-MPA, as the delivery of 3-MPA during steady-state can be held constant 
allowing for fewer variables when analyzing neurotransmission.  Following termination 
of the 3-MPA perfusion, there is an exponential clearance of 3-MPA from the probe.  The 
percent delivery of 3-MPA was on average 19.7 ± 8.4% across all three brain regions.  
Based upon the delivery of 3-MPA, on average the concentration of 3-MPA delivered to 
the brain was 2mM.  This is only a semi-quantitative concentration of 3-MPA, as there is 
a concentration gradient of 3-MPA down the length of the probe as well as out into the 
brain.  The concentrations of 3-MPA in the striatum and hippocampus during systemic 
dosing of 3-MPA were 125 and 175 µM respectively.    
 In the three probe experiments, when 3-MPA was administered through one 
probe, it was not detected in either of the other two probes.  This was important, as it 
shows that any changes that were seen in the other brain regions were not due to 3-MPA 
directly, but rather projections from one region to another.  This also supports the local 
dosing regime of 3-MPA.  3-MPA would be detected at all three probes during systemic 
dosing.  By administering 3-MPA through the probe, one can generate neurochemical 
changes in a defined region. 
	   87	  
(A)	  
(B)	  
Figure 3.5 Delivery of 10mM 3-MPA (µg/min) to the striatum 
of anesthetized (A) and awake (B) rats. 
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(A)	  
(B)	  
 
Figure 3.6 Delivery of 10mM 3-MPA (µg/min) to the 
hippocampus of anesthetized (A) and awake (B) rats. 
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Figure 3.7 Delivery of 10mM 3-MPA (µg/min) to the locus 
coeruleus of anesthetized rats. 
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3.2.2 Striatum Amino Acids  
3.2.2.1 Striatum Amino Acids in Anesthetized Rats 
 Due to trauma from probe implantation during surgery, neurotransmitter levels 
need to be allowed to return to basal levels before dosing [39, 40].  Therefore, one of the 
first studies monitored changes in amino acid and catecholamine neurotransmitter levels 
immediately after probe implantation.  Figure 3.8 shows the levels of amino acids and 
neurotransmitters returning to baseline following probe implantation.  From these data it 
was concluded that, following probe implantation, the probe will be perfused with aCSF 
for four hours prior to collection of background samples.  
 Figure 3.9 shows a control experiment in the striatum (n=3 rats), where aCSF 
was perfused through the probe for four hours following probe implantation, and aCSF 
continued to be perfused while collecting six 10 minute background samples followed by 
two hours of collections in five minute increments.  There are slight increases in aspartate 
during the third hour of collecting samples, which would correspond to the second hour 
of perfusing 3-MPA, however this increase is due mainly to one rat.  The changes in 
amino acids are expected to occur during the fifty minutes of dosing, and during this time 
period in the control experiment there are no large changes in the amino acids.  In 
addition, while there are small changes, the changes that are expected to be seen in test 
animals will be much larger than anything observed in the control rats.  
 Figure 3.10 shows the changes in amino acids during perfusion of 10mM 3-MPA 
through the microdialysis probe.  There was a 15-fold increase in glutamate following 
perfusion of 10mM 3-MPA.  
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Figure 3.8 (A) striatum amino acids return to basal and (B) striatum 
catecholamines return to basal following probe implantation [1]. 
(A)	  
(B)	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Figure 3.9 aCSF control assessments in the striatum of 
anesthetized rats (n=3).  
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The changes in glutamate were significant from basal at both p<0.05 and p<0.01.  
There was also a 5-fold increase in GABA following 3-MPA perfusion.  This increase in 
GABA was unexpected considering the mechanism of action of 3-MPA on GAD; 3-MPA 
is an inhibitor of the GAD enzyme.  Some of the GABA data points were significant 
from basal at p<0.05.  Unlike glutamate, GABA levels remain elevated, after the 
perfusion of 3-MPA was terminated.  Aspartate, an excitatory amino acid, similar to 
glutamate, increased 10-fold.  Most aspartate data points are significant from basal at 
p<0.01. Arginine and alanine are neither excitatory or inhibitory amino acids.  As would 
be expected there are no significant changes in either arginine or alanine.   
 
3.2.2.2 Striatum Amino Acids in Awake Rats 
 Figure 3.11 shows the changes in amino acids in the striatum of awake rats. There 
was a 250-fold increase in glutamate accompanied by a 50-fold increase in GABA. There 
was also a 20-fold increase in aspartate.  Alanine remained around basal levels.  Due to 
the large changes, the arginine peak could not be integrated as there were large peaks co-
eluting.   Glutamate, GABA, and aspartate were significant from basal at p<0.05 and 
p<0.01.   
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Figure 3.10 10mM 3-MPA perfusion in the striatum of anesthetized rats.  (A) 
Changes in Glu and GABA and (B) changes in aspartate, arginine, and alanine 
(n=14 rats). 10mM 3-MPA was perfused beginning at t = 0 minutes and the 
perfusion was stopped at t = 50 minutes.   
(A)	  
(B)	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(A)	  
(B)	  
Figure 3.11 10mM 3-MPA perfusion in the striatum of awake rats.  (A) 
Changes in Glu and GABA and (B) changes in aspartate, arginine, and alanine 
(n=14 rats). 10mM 3-MPA was perfused beginning at t = 0 minutes and the 
perfusion was stopped at t = 50 minutes.   
	  
	   96	  
3.2.2.3 Striatum amino acid projections into the hippocampus 
 As predicted, there were no significant changes in the amino acids in the 
hippocampus while dosing in the striatum.  Figure 3.12 shows changes in the 
hippocampus while dosing in the striatum.  While GABA does increase roughly 2-fold, 
these changes were variable from rat to rat and the increases are mostly due to only two 
of the five rats studied.  In the other three rats, GABA decreased slightly.  The large error 
bars seen in several of the aspartate data points were due to one rat.  Alanine was very 
stable, ranging from 94-108% of baseline over the course of the experiment.  
 
3.2.2.4 Striatum amino acid projections into the locus coeruleus 
 Figure 3.13 shows the changes in amino acids in the locus coeruleus while dosing 
in the striatum. Glutamate remained around basal levels with the exception of roughly 3 
data points corresponding to the 69, 74, and 79 minute samples.  This increase was only 
seen in one rat and was seen in aspartate and alanine as well.   GABA actually decreased 
in all 3 rats to under half of basal.  This decrease was not expected; as was stated before, 
there are few projections into the locus coeruleus and the striatum is not one of them.  
There have been a few studies indicating that norepinephrine has a role in decreasing the 
synthesis of GABA [41].  Studies looking into the interaction of GABAergic and 
noradrenergic receptors suggest there is a link between the two [42-45], where GABAA 
receptor agonists act to increase the release of norepinephrine and GABAB receptor 
agonists decrease the release of norepinephrine [44, 46].  GABAA and GABAB receptors 
may interact with both the presynaptic and postsynaptic noradrenergic terminals [47].  
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Other studies have been shown an inverse relationship between GABA and 
norepinephrine.  Increases in GABA have been shown to decrease norepinephrine 
release, while decreases in GABA result in an increase in norepinephrine [48, 49].  This 
relationship between GABA and norepinephrine could explain the decrease of GABA in 
the locus coeruleus.  Since the locus coeruleus is the main synthesis site of 
norepinephrine in the brain and contains a high number of noradrenergic neurons 
compared with other types of neurons, the decrease in GABA might be due to this 
relationship.     
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(A)	  
(B)	  
Figure 3.12 Striatum projections into the hippocampus.  (A) Glutamate 
and GABA.  (B) Aspartate, arginine, and alanine. 
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(A)	  
(B)	  
Figure 3.13 Striatum projections into the locus coeruleus.  (A) 
Glutamate and GABA.  (B) Aspartate, arginine, and alanine. 
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3.2.3 Hippocampus Amino Acids 
3.2.3.1 Hippocampus Amino Acids in Anesthetized Rats 
 The same experimental procedure was followed in the hippocampus as in the 
striatum.  Figure 3.14 shows the control experiment where aCSF was perfused through 
the probe for entire length of the experiment.  Changes in the amino acids during 
perfusion of aCSF are small and random; no trends are observed across all 3 rats.  As 
with the striatum, changes in the amino acids in these control experiments are negligible 
compared to what is seen in the dosed animals.   
Figure 3.15 shows the changes in amino acids during dosing of 10mM 3-MPA in 
the hippocampus.  The 7-fold increase in glutamate is smaller than what was seen in the 
striatum, but glutamate remains elevated during the extent of 3-MPA dosing, while in the 
striatum glutamate peaks and levels begin to fall before the perfusion of 3-MPA is 
stopped. Glutamate levels are significant from basal at both p<0.05 and p<0.01.  GABA 
levels are elevated roughly 2-fold, again smaller than the 5-fold changes seen in the 
striatum.  GABA is only signicantly different from basal levels (p<0.05) at one time 
point.  Additionally, GABA returns to baseline, and even goes below 100% towards the 
end of collection, while in the striatum GABA levels remain elevated the length of the 
experiment.  There is a nearly 6-fold increase in aspartate in the hippocampus of 
anesthetized rats.  These changes are significant at both p<0.05 and p<0.01.  In general 
the changes in amino acids levels in the hippocampus are half of what was seen in the 
striatum.  As with the striatum, the changes in glutamate and aspartate were expected.  
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Again, the increase in GABA was not expected, however it was much smaller in the 
hippocampus.  
 
3.2.3.2 Hippocampus Amino Acids in Awake Rats 
 As with the hippocampus in anesthetized rats, as well as the striatum in 
anesthetized and awake rats, glutamate, GABA, and aspartate all increased.  Figure 3.14 
shows the data for the hippocampus in awake rats.  Glutamate and GABA levels 
remained elevated for the length of 3-MPA perfusion.  However, the error bars are large 
and glutamate and GABA were only significant at p<0.05 for a couple of time points.  
Interestingly, unlike any other brain region, there are large increases in arginine and 
alanine, which are neither excitatory nor inhibitory amino acids.  Arginine increases 15-
fold while alanine increases 20-fold.  These increases could point towards excitotoxicity 
for the neurons, where they are dumping all their intracellular components, hence the 
increase in all amino acids, even those that have no effect on excitation/inhibition in the 
neuron.   
 
3.2.3.3 Hippocampus amino acid projections into the striatum 
Figure 3.17 shows the change in amino acids in the striatum while dosing 3-MPA in the 
hippocampus.  As expected there are no significant changes in the striatum.  Glutamate 
remains around basal, between 84-111% of baseline throughout the experiment.  There is 
an increase in GABA at the end of the experiment, but this is due to one rat.  Also, these 
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increases in GABA do not correspond to the time points where 3-MPA is administered in 
the hippocampus.  Aspartate, arginine, and alanine remain close to basal levels 
throughout the experiment.   
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Figure 3.14 aCSF control experiment in the 
hippocampus of anesthetized rats (n=3). 
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Figure 3.15 10mM 3-MPA perfusion in the hippocampus of anesthetized 
rats.  (A) Changes in Glu and GABA and (B) changes in aspartate, 
arginine, and alanine (n=9 rats). 10mM 3-MPA was perfused beginning 
at t = 0 minutes and the perfusion was stopped at t = 50 minutes.   
 
(A)	  
(B)	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(A)	  
(B)	  
Figure 3.16 10mM 3-MPA perfusion in the hippocampus of awake rats.  
(A) Changes in Glu and GABA and (B) changes in aspartate, arginine, 
and alanine (n=5 rats). 10mM 3-MPA was perfused beginning at t = 0 
minutes and the perfusion was stopped at t = 50 minutes.   
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3.2.3.4 Hippocampus amino acid projections into the locus coeruleus 
 Figure 3.18 shows the changes in amino acids in the locus coeruleus while 
administering 3-MPA in the hippocampus.  Glutamate remains around basal levels, as 
does arginine.  Alanine and aspartate increase slightly, however the increase in aspartate 
is due mostly to one rat, and a spike in aspartate for one time point in another rat.  
Alanine increases to around 150% of basal.  The most interesting finding is the decrease 
in GABA.  This is the same magnitude decrease (down as low as 50% of basal) that was 
seen in the locus coeruleus when dosing 3-MPA in the striatum (See section 4.2.1.2 for 
discussion).  Again, this decrease was not expected, as there have been no pathways 
discovered from the hippocampus to the locus coeruleus.  
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(A)	  
(B)	  
Figure 3.17 Hippocampus projections into the striatum.  (A) Glutamate 
and GABA.  (B) Aspartate, arginine, and alanine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   108	  
(A)	  
(B)	  
Figure 3.18 Hippocampus projections into the locus coeruleus.  (A) 
Glutamate and GABA.  (B) Aspartate, arginine, and alanine. 
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3.2.4 locus coeruleus Amino Acids  
3.2.4.1 locus coeruleus Amino Acids in Anesthetized Rats 
Figure 3.19 shows the amino acids in the locus coeruleus of anesthetize rats.  The 
results in the LC were surprising.  The 4-fold increase in GABA was similar to that 
which was seen in the striatum and hippocampus. However, the changes in glutamate 
were not expected, based upon the action of 3-MPA on GAD, but also based upon what 
was seen in the striatum and hippocampus.  Glutamate increased in all 5 rats; however, 
the extent to which it increased varied widely.  In two rats, glutamate increased to 315% 
and 260% of basal.  In the other three rats, increases in glutamate were modest, a less 
than 1.5-fold increase.  In all five rats following perfusion of 3-MPA (from the 85 minute 
sample on), glutamate decreased to below 100%.  Glutamate went as low as 60% of basal 
by the end of the experiment in one rat.  While the average increase of glutamate for all 5 
rats reached 171% of basal, these changes were substantially smaller than the 15 and 7-
fold increases seen in the striatum and hippocampus.  There was a 2-fold increase in 
aspartate in the LC, but again this was much smaller than the 10 and 6-fold changes seen 
in the striatum and hippocampus.   
On average, the concentrations of glutamate in the locus coeruleus are not 
significantly different from the concentrations in both the striatum and the hippocampus.  
Studies have found that glutamate concentrations, measured by microdialysis, in the 
locus coeruleus are as low as 0.90 ± 0.20 uM, more than 3-times less than the 
concentrations in the striatum and hippocampus [50].  It would seem from these reports 
that data that there is plenty of glutamate for neurons in the LC to release, however the 
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are under the curve (AUC) for the increase in glutamate in the locus coeruleus is so much 
less than for the striatum and the hippocampus might mean this is not the case.  Studies 
have been done to determine the content of GAD in the striatum, hippocampus, and LC.  
The content of GAD is relatively the same in the striatum and hippocampus [51].  There 
is also 
significant expression of GAD in the LC; it has been quantified by Majumdar et al. [52, 
53].   
Therefore, it seems that lack of glutamate or GAD expression in the LC cannot 
explain the small increase in glutamate seen in the LC upon perfusion of 3-MPA.   
 
3.2.4.2 locus coeruleus amino acid projections into the striatum 
Figure 3.20 shows the changes in the striatum while dosing 3-MPA in the locus 
coeruleus.  There are no changes in glutamate, arginine, and alanine.  There is an increase 
in aspartate, however, this increase is mostly due to one rat and it does not follow the 
time course of 3-MPA administration.  As was seen in the locus coeruleus, there is a 
decrease in GABA; however this decrease would not be statistically different from basal 
levels.   
 
3.2.4.3 locus coeruleus amino acid projections into the hippocampus 
Figure 3.21 shows the changes in amino acids in the hippocampus while dosing 3-
MPA in the locus coeruleus.  Glutamate remains at basal levels throughout the 
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experiment.  Arginine and alanine remain around basal levels as well.  Aspartate 
increases, though the increase in aspartate during the second hour (60-120 minutes) is due 
to an increase in one rat.  Also, the increase in aspartate shortly after starting to 
administer 3-MPA is due to an increase in aspartate in one rat. 
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(B)	  
(A)	  
Figure 3.19 10mM 3-MPA perfusion in the locus coeruleus of 
anesthetized rats.  (A) Changes in Glu and GABA and (B) changes in 
aspartate, arginine, and alanine (n=14 rats). 10mM 3-MPA was 
perfused beginning at t = 0 minutes and the perfusion was stopped at t 
= 50 minutes.   
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(B)	  
Figure 3.20 locus coeruleus projections into the striatum.  (A) 
Glutamate and GABA.  (B) Aspartate, arginine, and alanine. 
(A)	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(B)	  
Figure 3.21 locus coeruleus projections into the hippocampus.  (A) 
Glutamate and GABA.  (B) Aspartate, arginine, and alanine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A)	  
	   115	  
3.2.5 Amino Acids in Anesthetized Versus Awake Rats 
 The increases in glutamate, GABA, and aspartate were much larger in awake 
compared with anesthetized rats.  Differences in amino acids release in awake versus 
anesthetized rats is most likely due to the action of ketamine, the anesthetic used in 
anesthetized experiments.  Glutamate receptors can be categorized into two groups, 
ionotropic and metabotropic receptors.  Ionotropic receptors directly gate channels and 
allow the passage of ions and metabotropic receptors are gated by secondary messengers.  
There are three major types of ionotropic receptors: NMDA (N-methyl-D-aspartate), 
AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid), and kainate (kainic 
acid), all named after the ligands which activate them [4, 22, 54].  AMPA and kainite 
receptors are often referred to as non-NMDA receptors.  Glutamate binds to NMDA 
receptors allowing the passage of Na+, K+, and Ca+2 ions.  This leads to depolarization 
and an excitatory effect.  Blockage of NMDA receptor glutamate binding has been shown 
to result in decreased excitatory transmission [55, 56].  Ketamine, an NMDA antagonist, 
is the anesthetic used in the anesthetized experiments.  It has been characterized as an 
uncompetitive NMDA channel blocker [57].  Ketamine has also been shown to inhibit 
voltage-sensitive Ca+2 channels, which also suppresses excitatory transmission [58, 59].  
Ketamine has been shown in many studies to decrease glutamate release [60, 61].  
Kitayama et al. showed that in the presence of excess K+ (40mM) to evoke release of 
glutamate, ketamine blocked this release in a dose-dependent manner.   
 In rat experiments with ketamine as the anesthetic, this could explain the 
decreased release of glutamate.  It should be noted that in both the anesthetized and 
awake experiments, the basal levels of glutamate are on average the same.  This would 
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point to the fact that basal levels of glutamate have not been altered by the use of 
ketamine, but rather it is any subsequent release that is inhibited.  From these data it can 
be concluded that, if at all possible, experiments should be performed in  awake rats, as 
the use of ketamine in anesthetized rats masks the effect of 3-MPA.    
  
3.2.6 Inhibitory surround 
The data show an increase in excitation, via the increase in glutamate, as can be 
seen in Figure 3.20.  However, looking at the amino acids individually there is also an 
increase in inhibition from release of GABA.  The idea of an inhibitory surround, which 
surrounds the seizure focus, has received widespread acceptance, while there may be an 
increase in excitation in the seizure focus, there is a corresponding inhibition in the 
inhibitory surround [62-65].  Figure 3.21 illustrates the seizure focus and the inhibitory 
surround [22].  Inhibition in the inhibitory surround is thought to be a mechanism in 
stopping the spread of seizures from one brain region to surrounding tissue, as studies 
have shown that blockage of inhibition in the inhibitory surround is needed for the spread 
of epileptiform activity [64, 66].  Newer studies seem to support the concept that long 
range inhibition appears to limit excitability of neurons outside the focus [67, 68]. When 
excitation begins to break down the inhibition from the inhibitory surround, seizures can 
propagate from the focus to surrounding tissue [22, 69]. 
The idea that there could be inhibition within epileptogenic areas is not new [70-
73] and it occurs due to neuronal organization around a region of hyperexcitability [74-
76].  Studies in the cat cortex have shown that stimulation at a single point can lead to 
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inhibition throughout all cell layers up to 10mm away [77, 78].  While there appears to 
recurrent excitation in the hippocampus [21, 79, 80], and presumably in other regions, 
recurrent inhibition is widespread in the hippocampus and appears to override excitation 
[81-84]. 
The best explanation for the increases in GABA seen upon perfusion of 3-MPA 
has to do with the presence of the inhibitory surround.  When administering drugs 
through the microdialysis probe, the area surrounding the probe that is affected is very 
small.  If the excitatory effect of 3-MPA on the neurons surrounding the probe is large, 
but the number of total neurons being affected is considerably small, the surrounding 
neurons might overcompensate by releasing excess GABA to counteract the large 
increases in glutamate seen in the seizure focus.  While there has been studies looking at 
the inhibitory surround, most of these have involved excitatory postsynaptic potentials 
(EPSPs) and inhibitory postsynaptic potentials (IPSPs) [65, 85, 86].  While some work 
has been done investigating metabolic changes in the inhibitory surround [62], few 
studies have been done looking at inhibitory neurotransmission in the surround.  The 
diffusion coefficient of GABA has been reported to be 0.3 x 10-6cm2/s [87].  Based upon 
this diffusion coefficient it is plausible that GABA released in the inhibitory surround to 
diffuse to the probe and account for the increase in GABA seen in these data.  GABA 
begins to increase in the 10 minute sample during local administration of 3-MPA in the 
striatum.  Based upon the above diffusion coefficient for GABA, it would diffuse 0.2mm 
during that time.  As stated above, point excitation can lead to inhibition 10mm away [77, 
78].  An interesting study would be to place probes at different distances from the dosing 
probe and measure changes in GABA. 
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Figure 3.22 Glutamate/GABA ratio in the striatum of 
anesthetized rats (n=14 rats). 
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Figure 3.23 Illustration of the inhibitory surround. Neuron labeled 
(*) in the seizure focus has electrical discharges which can also 
activate neuron other neurons (**).  The first neuron in the seizure 
focus (*) can activate inhibitory GABA-ergic cells (***) in the 
inhibitory surround which through feedback mechanisms, can 
reduce the activity of (* and **) [22]. 
*	   **	   ***	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3.2.7 Source of extracellular glutamate and GABA 
There has been much debate regarding the source of glutamate and GABA 
collected with microdialysis.  There have been conflicting results regarding whether 
glutamate and GABA collected with microdialysis is due to neuronal release of the 
neurotransmitters or from glial cells.  Tetrodotoxin (TTX) is a compound often used to 
differentiate between neuronal or glial release.  TTX blocks voltage gated Na+ channels, 
thus preventing neuronal release of neurotransmitters.  While some studies using 
microdialysis have shown a decrease in GABA upon probe perfusion of TTX [88, 89], 
others have shown no net change[90-92], begging the question as to whether the GABA 
seen is from glial origin. Glutamate and GABA reside in two separate transmitter and 
metabolic pools.  GABA is synthesized from glutamate via GAD in the neurons.  
Glutamate and GABA can be released by the neurons and then are taken back up by glial 
cells [93, 94].    Compartmental analysis of glutamate has shown that glial cells contain 
15% of glutamate, while 50% resides in the neuronal metabolic pools and only 20-30% in 
the neurons ready for release [95].  However, it is hard to pinpoint whether the measured 
glutamate and GABA is due directly to neuronal release, slow reuptake, or what 
compartment it is coming from.  There are also many nonneurotransmitter uses for 
glutamate, as it is used as a precursor for protein and peptide synthesis, in fatty-acid 
synthesis, to regulate ammonia levels, and in the metabolism of carbohydrates [96].  
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3.2.8 GAD isoform compartmentalization 
 Prior research has shown that GAD is upregulated following seizures, likely a 
response to an increase in the amount of synthesized GABA [97, 98].  An increase in 
GAD expression would result in more turnover of glutamate to GABA, even in the 
presence of 3-MPA.  The function of GABA is also quite complicated.  GABA exists in 
two separate pools intracellularly, as metabolic GABA in the cytosol and as 
neurotransmitter GABA in the synaptic vesicles. This picture is complicated further 
because there are two different isoforms of GAD, GAD65 and GAD67 [99].  GAD65 
comprises around 70% of total GAD in the rat cortex and is predominantly found in the 
neuron terminals where it is used for vesicular GABA synthesis [100].  The less abundant 
GAD67 isoform is involved in metabolic GABA synthesis from glutamate [101].  
Therefore, the effect of 3-MPA dosing on GABA might depend on which cellular GABA 
component 3-MPA works on.  Finally, GAD65 is mostly in its inactive form under 
anesthesia in this 3-MPA model [102].  Since GAD65 is the isoform mostly found in 
neuronal terminals, this again raises the question as to whether the increases in GABA 
are due to the metabolic compartment.   
 
3.2.9 Striatum catecholamine neurotransmitters 
3.2.9.1 Striatum catecholamines in anesthetized rats 
 There is an increase in both dopamine and norepinephrine in the striatum during 
perfusion of 3-MPA.  The relationship between dopamine and norepinephrine are well 
known, as norepinephrine is converted to dopamine via the enzyme dopamine β-
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hydroxylase.  It is not surprising therefore, to see an increase in both dopamine and 
norepinephrine.  Figure 3.22 shows these data.  However, during systemic dosing of 3-
MPA there has been an increase in dopamine, but a decrease in norepinephrine [1, 103], 
while other microdialysis experiments have shown an increase release of norepinephrine 
[104-106].    
 Norepinephrine has been shown to play an important role in seizures. Fos 
induction, a gene used as a marker for neuronal activation, has been shown to be 
upregulated in the locus coeruleus following seizures [107-111].  Treatment with 
resperine, a monoamine depleting agent, lowered seizure threshold to several convulsants 
[112-115].  Selective depletion of norepinephrine and dopamine show that animals with 
depleted dopaminergic and noradrenergic neurons are more susceptible to seizures [30, 
112, 116, 117]. 
 The role of dopamine in seizures has been less defined.  Unlike norepinephrine, 
there is not an increase in fos expression in dopaminergic neurons following seizures 
[111, 118, 119].  Some studies have shown modification to dopaminergic neurons 
following seizures, such as an increase in firing [120], an increase in tyrosine 
hydroxylase (TH, responsible for the synthesis of L-DOPA, the dopamine precursor) and 
dopamine active transporter (DAT) [111], as well as an increase in D2 dopamine 
receptors and D2 receptor mRNA [121-123]. 
There has been a substantial amount of research investigating the connection 
between glutamate and dopamine.  The striatum receives glutamatergic projections from 
the cortex via the corticostriatal pathway and receives dopaminergic inputs from the 
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substantia nigra pars compacta via the nigro-striatal pathway [124].  Figure 3.23 
illustrates the neuronal circuitry and projections in the basal ganglia involving glutamate 
and dopamine [1, 125].  While most studies have demonstrated this relationship between 
dopamine and glutamate modulation [126-132], this is not universally accepted [133, 
134].  One crucial piece of evidence for glutamate modulating dopamine was the finding 
that dopamine synapses contain both AMPA and NMDA receptors, both binding sites for 
glutamate [135].  While the biochemical activity of 3-MPA is on the glutamate-GABA 
system, the increase in glutamate has a role in dopamine regulation.  Therefore, the 
increase in dopamine upon 3-MPA perfusion is not surprising.    
There is a small decrease in the dopamine metabolites, DOPAC and HVA, which 
supports findings elsewhere, where a decrease in these metabolites was seen following 
excitation of glutamate with NMDA [136]. 
 
3.2.9.2 Striatum catecholamine projections into the hippocampus 
All the catecholamines remain near basal levels in the hippocampus during 3-
MPA administration in the striatum.  An increase in norepinephrine and HVA around the 
20 minute mark is due to a spike in one rat.  Figure 3.24 show these changes 
 
3.2.9.3 Striatum catecholamine projections into the locus coeruleus 
As in the hippocampus, there are no significant changes in the catecholamine 
neurotransmitters in the locus coeruleus while dosing in the hippocampus.  The one 
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increase seen in DOPAC is due to one high point in one of the rats.  Figure 3.25 shows 
these changes 
 
3.2.10 Hippocampus catecholamines neurotransmitters 
3.2.10.1 Hippocampus catecholamine in anesthetized rats 
 Like the striatum, there was an increase in norepinephrine and dopamine in the 
hippocampus (Figure 3.26).  The metabolites DOPAC, 5-HIAA, and HVA remain around 
basal levels.   During systemic dosing of 3-MPA there was no increase in NE, an increase 
in DA, and also an increase in the metabolites [1].   
 
3.2.10.2 Hippocampus catecholamine projections into the striatum 
Figure 3.27 shows the changes in catecholamine neurotransmitters in the striatum 
while perfusing 3-MPA in the hippocampus.  The catecholamines remain around basal 
levels and there are no trends seen in any of the 3 rats. 
3.2.10.3 Hippocampus catecholamine projections into the locus coeruleus 
Figure 3.28 illustrates the changes in the catecholamines in the locus coeruleus 
while dosing in the hippocampus.  There are several peaks in norepinephrine that are seen 
in the locus coeruleus, however these are due again to larger increases in one rat and 
there were no trends in the data that suggest these changes are due to the 3-MPA 
administration.
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(A)	  
(B)	  
Figure 3.24 10mM 3-MPA perfusion in the striatum of 
anesthetized rats. (A) Catecholamines NE, DA, and metabolites 
5-HIAA, DOPAC, and HVA. (B) NE and DA (n=4 rats). 
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Figure 3.25 Glutamate and dopamine projections within the basal 
ganglia. GPe (pars externa of globus pallidus); SNc (pars compacts 
substantia nigra; SNr (pars reticula substantia nigra); STN 
(subthalmic nucleus); THA (thalamus); VTA (ventral tegmental 
area). 
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Figure 3.26 Striatum catecholamine neurotransmitter projections into 
the hippocampus.   
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Figure 3.27 Striatum catecholamine neurotransmitter projections into 
the locus coerueleus.   
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(A)	  
(B)	  
Figure 3.28 10mM 3-MPA perfusion in the hippocampus of anesthetized 
rats. (A) Catecholamines NE and DA. (B) Metabolites 5-HIAA, DOPAC, 
and HVA (n=4 rats). 
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Figure 3.29 Hippocampus catecholamine neurotransmitter projections 
into the striatum.   
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Figure 3.30 Hippocampus catecholamine neurotransmitter projections 
into the locus coeruleus.   
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3.2.11 locus coeruleus catecholamine neurotransmitters 
3.2.11.1 locus coeruleus catecholamines in anesthetized rats 
 Figure 3.29 show the changes in catecholamine neurotransmitters in the locus 
coeruleus. The locus coeruleus was studied because it is the main synthesis site for 
norepinephrine in the brain.  Levels of norepinephrine collected in the brain region were 
substantially higher than in the striatum and hippocampus.  Upon perfusion of 3-MPA, 
there was an approximately 3-fold increase in norepinephrine concentrations.   
 Quantitiation of dopamine in the locus coeruleus has not been widely reported.  It 
is thought this is due to the low concentrations of dopamine in this brain region [26].  
Dopamine was only detected in three of the five rats.   
 The metabolites remained around basal levels throughout the experiment.  The 
two spikes in DOPAC at 40 and 115 minutes were mainly due to large increases in one 
rat and are not considered significant events. 
 
3.2.11.2 locus coeruleus projections into the striatum 
Figure 3.30 shows the changes in the catecholamine neurotransmitters in the 
striatum while administering 3-MPA in the hippocampus. Dopamine remains at basal 
levels throughout; however there is an increase in norepinephrine.  This increase was 
seen across all the rats, around the same time point.  This was unexpected, as an increase 
in norepinephrine was not expected in the striatum.  Additionally, it was expected that 
increases in norepinephrine due to projections from the locus coeruleus should have been 
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seen during the administration of 3-MPA and not after the perfusion was pulled.  
Previous studies have employed a dual-probe microdialysis setup, where one probe was 
placed in the locus coeruleus and another in the prefrontal cortex to examine 
noradrenaline release [36].  In these studies there was no distinction in the time course of 
norepinephrine changes in either of the two regions.  Pudovkina et al. sampled at a rate of 
15 minutes and the changes in norepinephrine in the locus coeruleus and prefrontal 
cortex mirrored one another.  It is thus surprising to see an increase in norepinephrine in 
the striatum well after the perfusion of 3-MPA in the locus coeruleus has been stopped.  
However, there have been other studies that have shown that the GABAergic and 
noradrenergic relationship may have an effect here as well.  Intraventricular injections of 
GABA have shown that there is an initial decrease in norepinephrine, followed by a 
subsequent increase [137]. 
 
3.2.11.3 locus coeruleus projections into the hippocampus 
Figure 3.31 shows changes in catecholamines in the hippocampus while 
administering 3-MPA in the locus coeruleus.  This was the brain region that had inputs 
from the locus coeruleus, and thus an increase in norepinephrine was expected in this 
region; however, there were no increases in norepinephrine in the hippocampus while 
dosing 3-MPA in the locus coeruleus.   
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(A)	  
(B)	  
Figure 3.31 10mM 3-MPA perfusion in the locus coeruleus of anesthetized 
rats. (A) Catecholamines NE and DA. (B) NE, DA, and metabolites 5-
HIAA, DOPAC, and HVA (n=5 rats). 
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(A)	  
(B)	  
Figure 3.32 locus coeruleus catecholamine neurotransmitter projections 
into the striatum.  (A) norepinephrine and dopamine.  (B) DOPAC, 5-
HIAA, and HVA. 
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Figure 3.33 locus coeruleus catecholamine neurotransmitter projections 
into the hippocampus.   
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3.2.12 ECoG results 
 One of the advantages of the systemic dosing of 3-MPA is the large electrical 
signal that is produced.  In the systemic dosing model of 3-MPA screws were placed on 
the cortex.  This works because 3-MPA affects the brain globally and all the neurons are 
firing, so the signal is large enough to be detected in this manner.  However, with the 
local dosing of 3-MPA the signal is so small, even in the tissue surrounding the probe, 
that changes in electrical activity due to local perfusion of 3-MPA cannot be detected on 
the cortex.  The first experiment was to place individual wires down into the brain 
alongside the microdialysis probe to detect electrical activity as close to the probe as 
possible, with the idea that the only neurons that are firing are those immediately 
surrounding the probe.  Seizures were detected (25.3 ± 29.3 seizures) in 3 rats (2 awake 
and 1 anesthetized) in the striatum.  Seizures were detected in such a small number of rats 
that it was thought maybe this was due to placement of the wires.  Since the wires were 
not stereotaxically placed in the brain, it was unknown the final proximity of the wires to 
the probe itself.  With such a small area being affected by the 3-MPA, placement of the 
wires with respect to the probe was crucial in detecting seizures.  In addition, the role of 
the inhibitory surround could be a contributing factor as well.  If wires were placed in the 
surround as opposed to the seizure focus, no seizures would be detected.   
 Specially designed microdialysis probes with internal Ag/AgCl electrodes were 
then used with the potential to obtain electrical activity at the site of dosing.  Figure 3.32 
shows the design of the probes.  Figure 3.33 is raw ECoG data obtained from a the 
systemic dosing model of 3-MPA.  Two screws were placed on the cortex and a 
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microdialysis probe with an internal Ag/AgCl electrode was placed in the striatum.  The 
top two traces in Figure 3.33 are from the two screws on the cortex, while the bottom 
trace is from the probe electrode.  This trace was from after dosing of 3-MPA and 
seizures can be seen in all three traces.  Figures 3.34 and 3.35 shows the seizure detection 
algorithm output.  Figure 3.34 is from screws on the cortex, while Figure 3.35 is for the 
microdialysis probe electrode.  The systemic injection of 3-MPA was given at 30 minutes 
(1800 seconds).  The top graph is Figures 3.34 and 3.35 are the time-frequency maps for 
the power spectral density logarithm.  The bottom graph in these two figures is the 2-D 
time-frequency map.  The existence of seizures manifests itself in strip-like structure of 
spectral evolution time-frequency map because seizure is an abrupt increasing of 
oscillation power in some frequency bands. From this it was determined that these probes 
are functional and can detect electrical seizure activity.  From here these probes were 
used with the local dosing of 10mM 3-MPA.  However, as can be seen in Figure 3.36 
upon local dosing of 10mM 3-MPA in the locus coeruleus no seizures were detected.  
This same result holds true for recording ECoG activity in one of the control probes, no 
seizures were detected.  There was also a large band at 60 Hz, which is indicative of the 
large noise accompanying these samples.  Seizures were not detected in any of the rats 
where local dosing of 3-MPA was used.  This was most likely due in part to the 
significant amount of noise, as well as the small number of neurons that would be firing 
due to the local administration of 3-MPA.  Because of the large noise seen using the 
microdialysis probe electrodes in anesthetized animals, these probes were not used in 
awake and freely moving rats, as the noise component would be even more significant.   
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Figure 3.34 Diagram of microdialysis probe with internal 
Ag/AgCl working electrode [138].   
	   140	  
Figure 3.35 Raw ECoG data from screws on cortex (top 2 
traces) and internal microdialysis electrode (bottom trace) 
during systemic dosing of 3-MPA (60mg/kg bolus + 
50mg/kg constant infusion for 50 minutes). 
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Figure 3.36 ECoG data from screws on cortex during 
systemic dosing of 3-MPA (60mg/kg bolus + 50mg/kg 
constant infusion for 50 minutes). 
	   142	  
Figure 3.37 ECoG data from internal microdialysis 
Ag/AgCl electrode during systemic dosing of 3-MPA 
(60mg/kg bolus + 50mg/kg constant infusion for 50 
minutes).  
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Figure 3.38 ECoG data from internal microdialysis 
Ag/AgCl electrode during local dosing of 10mM 3-MPA in 
the locus coeruleus.  
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3.2.13 Local dosing of picrotoxin 
As stated previously, one of the reasons for a local administration of 3-MPA was 
to induce seizures in a locally defined brain region since these types of seizures, at least 
initially, are more clinically relevant [3].  However, as demonstrated in previous chapters, 
the significant problem with the local dosing of 3-MPA has been the inability to detect 
seizures.  It was generally thought that an increase in excitation over inhibition leads to 
seizures, however from the data presented here it appears that is not the whole picture.  
Obrenovitch et al. have explored the role of extracellular glutamate and its relationship to 
seizures and have shown that increasing extracellular glutamate 20-fold did not result in 
seizures [139].  This seem to support the data we have presented showing 5-200 fold 
increases in glutamate resulting in no seizure generation.  In addition, there are 
conflicting results regarding the action of glutamate in seizure generation, where studies 
have shown an increase, decrease, and no change in glutamate concentrations during 
seizures [139-141].    There are several plausible explanations for this.  It is possible that 
by administering 3-MPA through the probe, the number of neurons affected is so small 
that the signal produced from any seizure events are too small to detect.  One other 
possibility is that there aren’t any seizures being generated and an increase in excitation is 
only part of the picture leading to seizure generation.  This idea sheds light on the fact 
that maybe an altered balance between excitation/inhibition is important in seizure 
generation, but there are other factors that are important as well.  The purpose of these 
studies are to use a different convulsant, picrotoxin, which leads to seizure generation via 
a different mechanism to see if seizures can be detected.  If seizures can be generated 
using picrotoxin, this could lead to a greater understanding of the 3-MPA model and 
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seizure generation in general by leading to the conclusion that 3-MPA action on the 
excitatory/inhibitory balance in the brain is not the cause of seizures.   
Local dosing of 600µM picrotoxin, in aCSF, was performed in anesthetized rats, 
however no seizures were detected.  This result indicates that more than likely there is a 
problem with the electrode set-up.  Therefore, there is more method development that 
needs to be performed to measure seizures during local dosing.   
 
3.2.14 Brain histology 
 After experiments, rats were sacrificed and brains were harvested for histology.  
The brains were placed in a 10% neutral buffered formalin solution.  Probe placement as 
well as tissue damage was determined from brain slices.  Figure 3.39 shows histological 
slices from a representative rat brain.  These are two picture of a 2mm probe in the 
hippocampus after dosing 10mM 3-MPA in this region.  As can be seen in the top image, 
the probe is placed in the CA1 region of the hippocampus.  The lower image shows no 
signs of cell death, leading to the conclusion that these high concentrations of 3-MPA do 
not significantly damage the tissue. 
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Figure 3.39 Probe placement in CA1 of the hippocampus. 
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3.3 Conclusions 
 A consistent steady-state delivery of 3-MPA (in µg/min) was achieved in all three 
brain regions in both anesthetized and awake rats.  Local dosing of 3-MPA produced 
significant changes in amino acids and catecholamine neurotransmitters.  These changes 
were substantially larger than those seen with systemic dosing of 3-MPA.  Glutamate 
increased 15-fold in the striatum of anesthetized rats and 250-fold in awake rats.  GABA 
also increased in the striatum of anesthetized and awake rats, 5-fold and 50-fold 
respectively.  This increase in GABA was not expected based on the mechanism of action 
of 3-MPA on GAD.  Glutamate and GABA both also increased in the hippocampus of 
anesthetized and awake rats, however these changes were slightly smaller than those seen 
in the striatum.  Glutamate increased only slightly (171% of basal) in the locus coeruleus 
of anesthetized rats, while GABA increased 4-fold.   
 Catecholamine neurotransmitters changed as well during local dosing of 3-MPA.  
Dopamine and norepinephrine increased in all three brain regions in anesthetized rats, 
while 5-HIAA, HVA, and DOPAC remained around basal levels.   
 Seizures were not detected in any of the experiments using local dosing of 3-
MPA.  It was suggested that this was due to the small number of neurons affected by the 
local dose of 3-MPA as well as the significant background noise during collection.   
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Chapter 4 
Multiple Dosing of 3-MPA 
 
4.1 Introduction 
4.1.1 Background and Significance 
 Glutamate activates 3 types of ionotropic receptors, NMDA (N-methyl-D-
aspartate), AMPA (α-amino-3-hydroxy-5-methy-4-isoxazole propionic acid), and kainite 
(KA) receptors.  Previous work in our lab has shown the effects of both local and 
systemic dosing of 3-MPA on glutamate.  The effects of glutamate in particular are of 
importance because of its role in excitotoxicity and subsequent cell death.  Glutmate 
excitotoxicity leads to an influx of calcium into the cell [1-3], as well as an increase in 
reactive oxygen species and cell death [4].  There is evidence that shows cells can 
respond in several ways.  The first possibility is desensitization.  Desensitization is the 
process by which  further binding of the ligand to a receptor leads to decreased  
effectiveness of the receptor [5].  If a receptor becomes desensitized, it is no longer able 
to gate the release or reuptake of neurotransmitters, which in the case of glutamate would 
lead to excitotoxicity.  Another pathway is sensitization of the receptor.  Sensitization 
refers to an increase in response over time to a stimulus that originally did not elicit a 
response.  The third option is the idea of neural protection/neural modulation where cells 
respond in such a way to limit the negative effects of excitotoxicity.  Neural adaptation 
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can be thought of as short-term depression, but can also occur over a longer period of 
time with modulation in enzyme activity and protein synthesis. 
 Investigating multiple seizure events is important because clinical studies have 
shown the increased likelihood of subsequent seizures following the first unprovoked 
event [6-8].  It is often the subsequent excitotoxicity of glutamate and Ca+2 that kills 
neurons rather than the seizures themselves [9, 10].  However, there has not been 
sufficient work to determine the role of the neurons during subsequent seizure and 
excitation events to determine their course of action.  In this study 3-MPA was 
administered twice to determine the neuronal changes during two separate events.   
 
4.1.2 Desensitization 
 Desensitization of cells can result from a variety of sources.  There is evidence 
that with desensitization, there is poor reuptake of glutamate from the post-synaptic space 
[11, 12].  If glutamate remains in the AMPA receptor longer than it is gated open, 
excitotoxicity can result [13].  NMDA receptors desensitize relatively slowly compared 
to AMPA and kainic receptors, which can desensitize on the order of milliseconds [14].  
One of the mechanisms of receptor desensitization appears to be a conformational change 
in the form of a rearrangement of the dimer interface upon binding [15].  Glutamate 
excitotoxicity can occur at relatively low concentrations.  Excitotoxicity has been seen 
with extracellular levels of glutamate as low as 2-5 µM [16, 17].  Swelling and apoptosis 
of the cells have been seen at levels below 25 µM with fast necrosis setting in at 
concentrations of glutamate over 100 µM [18].  The idea of excititoxicity is important in 
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seizures, because upon subsequent seizure events, cells become more easily excitable.  In 
fact in many cases, it is the excitotoxicity which is more damaging than the seizures 
themselves.  
 
4.1.3 Sensitization 
 Sensitization is often referred to as the “kindling effect” in that the mechanism of 
sensitization is closely related to the kindling mechanism for seizure development.  
Sensitization occurs when a stimulus that initially does not elicit a response, over time 
generates a response [19].  In the kindling model of epilepsy, sub-convulsive doses of a 
convulsant are given repeatedly over a period of time.  Over time the animal becomes 
“sensitized” to the convulsant and these sub-convulsant doses develop into seizures [20-
23].  This idea was first described in 1961 by Sevillano et al. where small current 
stimulation in the hippocampus resulted in an intensification of seizures as a result of 
stimulation [24].  This idea can be applied to drug application for seizure induction.  
Repeated dosing of a drug which elicits an increase in glutamate, in this case 3-MPA, 
could result in more substantial release of glutamate upon subsequent dosing.   
 
4.1.4 Long-term potentiation 
 Learning and adaptation manifest themselves in the behavior and actions of an 
animal.  These changes, however, are due to changes in the nervous system, which are 
due to changes on the cellular level, neurons in particular [25].  Long-term potentiation 
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(LTP) was first described by Bliss et al. in 1973, where they showed that a brief period of 
high-frequency stimulation led to an increase in the synaptic connections between 
neurons in the perforant path inputs in the entorhinal cortex to the dentate granule 
neurons in the dentate gyrus [26].  LTP has been shown to last for months and is another 
hypothesis to describe learned adaptation and explain synaptic plasticity.  The 
mechanisms of long-term potentiation, however, are still not well understood.  One 
unresolved question is whether the mechanism involves the pre-synaptic terminal, post-
synaptic terminal, or both.  Alterations on the presynaptic terminal could include the 
amount of neurotransmitter synthesized, number of vesicles released, kinetics of release, 
and reuptake.  Changes at the post-synaptic terminal could include up/down regulation of 
the number of receptors, as well as ion flow [25].  Other possible mechanisms underlying 
LTP include gene expression and protein synthesis, such as activity-regulated 
cytoskeleton-associated protein (Arc) [27].  Inhibiting protein synthesis has been shown 
to effect memory transduction [25].  LTP can be divided into two stages, early and late.  
Early stage LTP can last for about 1 hour and is independent of newly synthesized 
proteins, while late stage LTP can last for months and is dependent on protein synthesis 
[28].  Regardless of the mechanism, LTP is one way to describe learning and memory in 
cells.   
 
4.1.5 Short-term depression 
 Short-term depression is often due to altered feedback mechanisms.  
Neurotransmitters in high concentrations post-synaptically can act upon the pre-synaptic 
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terminals depressing further release [29, 30].  Communication between glial cells and 
neurons can be depressed [31-33] and vesicle sensitivity to Ca+2 can be adapted [34, 35]. 
 
4.1.6 Regulation of enzyme activity, proteins, and transporters 
 Studies have shown the marked decrease in glutamic acid decarboxylase activity 
(GAD) during seizures [36-38].  Long-term studies have also shown an upregulation in 
GAD weeks after seizures [39, 40].  This increase in GAD activity is thought to 
counteract the decrease in GABA by producing more GAD that will in turn lead to 
increased GABA levels. 
 Veiscular glutamate transporter 1 (VGLUT1) and vesicular GABA transporter 
(VGAT) are both amino acid transporters which help to supply vesicles with the amino 
acids for release.  Research has shown an upregulation of VGAT with a subsequent 
downregulation of VGLUT1, one week following pilocarpine-induced seizures [41].  
Again, the purpose of this regulation is to increase the amount of GABA in the brain. 
 
4.1.7 Experimental procedure 
 In past experiments, 10mM 3-MPA was perfused through the probe for 50 
minutes followed by aCSF for the remaining 70 minutes.  In the multiple dosing 
experiments, after 60 minutes of basal collection 10mM 3-MPA was perfused through the 
probe for 25 minutes followed by 35 minutes of aCSF, followed again with 25 minutes of 
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10mM 3-MPA, and finally another 35 minutes with aCSF.  The sampling rate and 
detection schemes were the same as discussed previously.   
 
4.2 Results and Discussion 
4.2.1 3-MPA 
 The perfusion time of 3-MPA was divided into two equal 25 minute intervals.  
The total perfusion time of 50 minutes was held constant so that data could be compared 
between the single 50 minute perfusion of 3-MPA and the multiple dosing regimen.  If 3-
MPA was perfused longer in one experiment compared to the other, excitation and 
release of glutamate could not be compared directly between experiments.  The perfusion 
was divided into two equal intervals so that the change in neurotransmitters from the first 
25 minute perfusion could be compared with the changes during the second 25 minute 
perfusion.  If one interval was longer than the other changes in neurotransmitters could 
then be due to the total amount of 3-MPA delivered to the brain and not any changes in 
synaptic plasticity of the neurons between doses.   
Figure 4.1 shows the delivery of 10mM 3-MPA into the hippocampus of 
anesthetized rats.  As expected, the delivery of 3-MPA is biphasic with removal of 3-
MPA between the first and second administration and again during the final 35 minutes 
of the experiment.   The plateau in 3-MPA is similar to that seen in the single 50 minute 
dose of 10mM 3-MPA.  Based upon this, the total amount of 3-MPA delivered to the 
brain during both 25 minute administration intervals is similar to that during the single 50 
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minute administration.  This was important to compare the multiple dosing with the 
single dose.   
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Figure 4.1 10mM 3-MPA delivered to the brain (µg/min) during 
multiple dosing of 3-MPA (n=4 rats). 
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4.2.2 Amino Acids 
 Figure 4.2 shows the changes in glutamate and GABA during the multiple dosing 
of 3-MPA.  There were two increases in both glutamate and GABA, however the 
increases are attenuated during the second administration of 3-MPA.  There was a 6-fold 
increase in glutamate during the first administration, followed by a 2.5-fold increase.  
GABA increased 2.5-fold during the first administration followed by almost a 2-fold 
increase during the second.  There was a correlation between the magnitude of glutamate 
release during the first administration and the magnitude of the attenuation during the 
second administration.  The error bars are significantly large due to one rat.  In this one 
rat glutamate increased 14-fold during the first administration of 3-MPA and 6-fold 
during the second.  The ratios for the increased glutamate release during the first 
administration compared to the second administration show that, although in this one rat 
the 14-fold increase was substantially larger than in any of the other rats, the ratio of the 
first increase to the second is similar, 2.76 compared to an average of 2.13 ± 0.71 for all 
four rats combined.   One reason for perfusing aCSF 35 minutes before the second 
administration of 3-MPA, in addition to the necessity of doing so to divide the 3-MPA 
administration into two equal 25 minute periods, was to allow glutamate levels to return 
to basal levels.  In three of the rats glutamate levels returned to basal: 101.1 ± 8.5%.  The 
only rat where this was not the case (returned to 211%), was again the rat where the 
increase in glutamate was the greatest.   
 The area under the curve for the release of glutamate in the hippocampus of 
anesthetized rats for the 50 minute perfusion of 3-MPA was calculated and compared to 
the release of glutamate in the multiple dosing regimen of 3-MPA.  The release of 
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glutamate was larger during the 50 minute perfusion, 39555 (% change x min), compared 
to 26592 (% change x min) for the multiple dosing regime.  Since 3-MPA was perfused 
for the same period of time, and roughly the same mass of 3-MPA was perfused during 
the 50 minute perfusion compared to the multiple dosing regimen, these results suggest 
that the reason for a smaller increase in glutamate during the multiple dosing regimen is 
not due to a lack of glutamate available for release, but rather points towards a 
neuroprotective role preventing further release of glutamate.   
 Figure 4.3 shows the changes in the other amino acids.  There was an 8-fold 
increase in aspartate during the first administration of 3-MPA followed by an attenuation 
in apartate during the second administration, which was a more modest 2-fold increase.  
The large error bars are due to one rat, again the rat where the increase in glutamate was 
the greatest.  These large error bars exist for arginine and alanine as well, both non-
excitatory and non-inhibitory amino acids.  With the exception of the 30 and 35 minute 
time points in the one rat, the alanine levels remain at basal levels, between 91 and 110 % 
of baseline.  Since this increase was only seen in one rat, this event was not significant.  
 Since the depression in signal seen in these experiments is on such a short-term 
basis, many of the explanations regarding protein synthesis and regulation of enzymes are 
not applicable in this case.  Upregulation in GAD was shown to occur on the timescale of 
one week, obviously too long to describe the changes seen here [39, 40].  Likewise, 
upregulation of VGAT and downregulation of VGLUT1 was shown to occur one week 
after seizures [41].  Therefore, there must be a short-term explanation for depression on 
the order of minutes and hours as opposed to days. 
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The most common explanations for short-term synaptic depression are vesicle 
depletion models.  The idea behind these models is that upon stimulation a fraction of the 
readily releasable vesicles are depleted.  Upon a second stimulation, the readily releasable 
pool (RRP) is a fraction of what was available upon the first stimulation [42, 43].  
Synaptic depression can also be due to release probability [44, 45], and the recycling of 
vesicles and whether reserves lie in the readily releasable pool or the reserve pool [46-
49].  Stevens et al. have shown that synaptic depression could be due to depletion of the 
readily releasable pool, requiring recycling and movement of vesicles from the reserve 
pool to the synapse for release [47].  There have been studies to determine the size of the 
pool.  There are various ways to ensure complete emptying of the RRP, either by a large 
depolarizing pulse, caged Ca+2, high-osmolarity solution, and repetitive stimulus trains 
[50-52].  In the CA1 portion of the hippocampus, the area targeted in our experiments, it 
has been estimated by electron microscopy that there are on average 10 vesicles in the 
RRP, however there is quite a bit of variability in this number even within the CA1 [52-
54].  While vesicle depletion models are often used to describe short-term depression, 
this model cannot not explain the depression seen in these experiments.  As stated above, 
based upon the area under the curve calculations for the release of glutamate during the 
50 minute perfusion versus the multiple dosing of 3-MPA, it appears that there was 
sufficient glutamate that was not released during the first administration of 3-MPA, 
suggesting that the RRP has not been depleted.   
 There have been studies showing that depression is independent of the magnitude 
of initial release and stimulation frequency, suggesting that there are pathways of 
depression that are not dependent upon vesicle depletion [55-57].  Specifically in 
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inhibitory rat synapses, a second release was not dependent upon the magnitude of the 
first [58].  Synaptic release has long been connected with an influx of Ca+2.  There is 
heterogeneous sensitivity of vesicles to the concentration of Ca+2 needed for vesicle 
fusion and release.  There is a hypothesis that vesicles can adapt their sensitivity to Ca+2, 
leading to depression [34, 35].  There is also homosynaptic inhibition, where the 
concentration of a neurotransmitter builds up to a level where it has an action on the pre-
synaptic terminal, in addition to the post-synaptic terminal, which leads to a negative 
feedback loop and synaptic depression [52].  One such example is the breakdown of 
ATP, found in high levels in vesicles, to adenosine which goes onto activate pre-synaptic 
adenosine receptors and leads to inhibition [29, 30]. Depression can also occur by the 
action of GABA on pre-synaptic GABAB receptors which will reduce Ca+2 influx upon 
subsequent stimulation.  Another possible pathway for depression is due to the interaction 
between neurons and glial cells.  Glial cells contain neurotransmitter receptor sites.  
Signaling can elevate Ca+2 levels in glial cells which results in release of substances 
from astrocytes which act on the pre-synaptic terminal to regulate neurotransmitter 
release.  Hippocampal cell culture research has shown that stimulation of glial cells leads 
to depression between the glial cells and neurons [32].  It is thought that this depression is 
due to Ca+2 evoked release of glutamate, which then acts on pre-synaptic metabotropic 
glutamate receptors [31-33].   
 From the studies performed here it is impossible to determine exactly what 
mechanism is causing this short-term depression.  With such large increases in glutamate 
upon administration of 3-MPA, it is plausible that there is a feedback mechanism where 
glutamate acts on the pre-synaptic terminal, thus depressing further release of glutamate.  
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(A)	  
(B)	  
Figure 4.2 Multiple Dosing of 10mM 3-MPA in the hippocampus of 
anesthetized rats.  (A) Glutamate and GABA full scale and (B) zoomed 
picture of glutamate and GABA for better detail (n=4 rats).  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	   173	  
(A)	  
(B)	  
Figure 4.3 Multiple Dosing of 10mM 3-MPA in the hippocampus of 
anesthetized rats.  (A) aspartate, arginine, and alanine full scale and (B) 
zoomed picture of arginine and alanine for better detail (n=4 rats).  
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4.2.3 Catecholamine neurotransmitters 
 Figure 4.4 shows the changes in catecholamine neurotransmitters during multiple 
dosing of 3-MPA.  There are two increase in norepinephrine, similar to that which is seen 
with glutamate.  Norepinephrine increased 5-fold during the first administration of 3-
MPA, returned to basal levels, and then increased 3.5-fold during the second 
administration.  These increases in norepinephrine make sense, during the 50 minute 
perfusion of 3-MPA in the hippocampus NE remained elevated during the entire 
administration.  This shows the relationship between 3-MPA dosing and release of NE.  
Dopamine increased roughly 2-fold during both administrations of 3-MPA.  The 
metabolites DOPAC, 5-HIAA, and HVA respond similarly as they do during the 50 
minute perfusion of 3-MPA, as can be seen in Figure 4.5. 
 Research has demonstrated a role in glutamate stimulated release of 
norepinephrine [59-61].  These results seem to be substantiated here, as the two increases 
in norepinephrine mirror the changes seen in glutamate.   
 
4.2.4 ECoG analysis 
 As with the single dosing regimen of 3-MPA, no seizures were detected during 
multiple dosing.  This can be seen in Figure 4.6.  See section 3.xx for a thorough 
discussion of ECoG data. 
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(A)	  
(B)	  
Figure 4.4 Multiple Dosing of 10mM 3-MPA in the hippocampus of 
anesthetized rats.  (A) catecholamine neurotransmitters full scale and 
(B) NE for better detail (n=4 rats).  
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Figure 4.5 Catecholamine metabolites during 10mM 3-MPA 
multiple dosing in hippocampus (n=4 rats). 
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Figure 4.6 ECoG data from internal microdialysis Ag/AgCl 
electrode during multiple dosing of 10mM 3-MPA in the 
hippocampus. 
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4.3 Conclusions 
 Multiple dosing of 3-MPA led to a similar delivery as the 50 minute 
administration period.  There were two increases for glutamate, corresponding to the two 
administration periods of 3-MPA.  The was an initial 6-fold increase in glutamate, 
followed by an attenuated 2.5-fold increase.  The area under the curve (AUC) for the 
second increase in glutamate was small than the first increase, however, the combined 
area under the curve for the two increases in glutamate was smaller than for the 50 
minute perfusion.  There was an attenuated increase for GABA and aspartate as well 
during the second administration of 3-MPA.  It was suggested that the attenuation in 
signal was not due to a vesicle depletion, rather some protective mechanism.  This short-
term depression could be due to Ca+2 sensitivity, a negative feedback loop due to buildup 
of transmitter in the post-synaptic cleft, the action of GABA on pre-synaptic GABAA 
receptors, and interaction between glial cells and neurons.   There were also large 
increases in norepinephrine.  It was suggested these increases could be due to the role of 
glutamate on norepinephrine release.  As with the single dose regimen of 3-MPA no 
seizures were detected.   
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Chapter 5 
Conclusions and Future Work 
 
5.1 Summary of Dissertation 
 Previous research in our laboratory involved a 
pharmacokinetic/pharmacodynamic study of a chemically-induced seizure model with 3-
MPA in rats [1, 2].  A steady-state model for 3-MPA administration was developed 
where a 60 mg/kg bolus dose was followed by a constant intravenous (i.v.) infusion of 50  
mg/kgmin-1 of 3-MPA for 50 minutes.  The concentrations of 3-MPA were measured in 
the blood, striatum, and hippocampus.  Steady-state concentrations of 3-MPA were 
achieved in the brain and the pharmacokinetics of 3-MPA in the blood and the brain were 
studied.  This was the first known study of the pharmacokinetics of 3-MPA in a 
chemically-induced seizure model.  By achieving steady-state concentrations of 3-MPA, 
the concentration/response variable was held constant when studying the neurochemical 
changes in the striatum and hippocampus.  As expected, 3-MPA inhibited the conversion 
of glutamic acid to γ-hydroxybutyric acid in vivo, resulting in an increase in glutamic 
acid and a decrease in γ-hydroxybutyric acid.  In addition to measuring the concentrations 
of 3-MPA and the subsequent neurochemical changes in the brain, ECoG recordings 
were made.  Thus, seizure number, intensity, and duration were correlated to the 
neurochemical changes.   
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 While this constant infusion model was an important first step in the development 
of 3-MPA epileptic seizure model, it is not very clinically relevant.  Research has shown 
that 70% of adult onset epilepsy patients present with partial (focal) seizures [3].  This 
means that the seizures and the effects thereof are localized in a specific brain region.  3-
MPA in this constant infusion model is administered to the entire brain, and thus its 
physiological and neurochemical changes are on a global scale as well.  The purpose of 
these studies was to develop a model where 3-MPA is dosed to a specific brain region so 
that the physiological and neurochemical changes can be monitored in a site specific 
manner, while not to disturbing the neurochemical balance in the brain as a whole. 
 
5.1. 3-MPA local dosing in the striatum, hippocampus, and locus coeruleus 
 Delivery of 10mM 3-MPA was consistent through all three brain regions, in both 
awake and anesthetized rats.  Upon administration of 3-MPA there was an increase in 
both glutamate and GABA.  The increase in glutamate compared to baseline in the 
striatum of anesthetized rats was 15-fold following local delivery, compared to a 2-fold 
increase following systemic dosing of 3-MPA.  Glutamate increased 7-fold in the 
hippocampus of anesthetized rats as well.  The increases in glutamate were much larger 
in awake rats, 200-fold in the striatum and 25-fold in the hippocampus.  It is possible that 
the increased levels of glutamate in awake rats are related to the use of ketamine, a 
NMDA antagonist, as the anesthetic utilized in these experiments has been shown to 
decrease excitatory transmission and inhibit voltage sensitive Ca+2 channels [4-10].  The 
increase in GABA in these experiments was unexpected and it may be due to the role of 
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the inhibitory surround.  The inhibitory surround is the region of brain tissue surrounding 
the seizure focus where there is an increase in inhibition to prevent the spread of the 
epileptic focus to the surrounding tissue.  When dosing 3-MPA through the probe, the 
region affected is so small that GABA released in the inhibitory surround can diffuse to 
the probe and would result in the increase in GABA seen at the 3-MPA dosing probe.  
Aspartate, another excitatory amino acid, increased as well in the striatum and 
hippocampus of both awake and anesthetized rats.  In the locus coeruleus, there was 
again an increase in both glutamate and GABA; however, the increase in GABA was 
larger than glutamate.  There is a significant pool of glutamate (µM levels) and 
expression of glutamic acid decarboxylase (GAD) in the locus coeruleus; thus this does 
not seem to explain the small increase in glutamate in this region, compared to the larger 
increases in the striatum and hippocampus [11-14]. 
 There was an increase in norepinephrine and dopamine in all three brain regions 
in anesthetized rats.  The increase in norepinephrine was not seen with the systemic 
dosing of 3-MPA and the role of norepinephrine in the locus coeruleus (the main 
synthesis site of norepinephrine in the brain) was a major reason for studying this brain 
region with the 3-MPA model.  The increase in dopamine was not surprising, considering 
the increase seen with the systemic 3-MPA model, as well as the neuronal relationship 
between glutamate and dopamine [15-21]. 
 As discussed above, one of the advantages of the local dosing 3-MPA model is 
that any seizure activity and subsequent neurotransmitter changes would be isolated to a 
small brain area, when compared to systemic injections where the whole brain is effected.  
One way to show that this was indeed the case was to dose 3-MPA through the probe in 
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one brain region, but also collect samples in the other two brain regions where only aCSF 
was being perfused, as a control.  If 3-MPA was indeed acting locally, there should be 
minimal changes in the other brain regions, unless there were projections present from 
one brain region to another.   
 In most brain regions, administration of 3-MPA did not effect the levels of amino 
acids and catecholamine neurotransmitters in other regions.  These results show that 
administration of 3-MPA through the probe produced only local neurochemical changes 
and does not effect the brain in a global manner.   
 When administering 3-MPA in either the striatum or hippocampus, there is a 
subsequent decrease in GABA in the locus coeruleus.  It has been suggested this might be 
due to the role of norepinephrine in GABA synthesis and the interaction between 
GABAergic and noradrenergic neurons [22-28].  Also, when administering 3-MPA in the 
locus coeruleus there was a subsequent increase in norepinephrine in the striatum.  This 
increase was after the termination of 3-MPA dosing and was not expected as literature 
has not indicated there are projections from the locus coeruleus to the striatum. 
  Seizures were detected in three rats using copper wires placed in the brain 
alongside the microdialysis probe.  However, there were many rats in which no seizures 
were detected.  It was thought that this might be due to the placement of the wires and 
their proximity to the probe itself.  For this reason specially designed probes were used 
with an internal Ag/AgCl working electrode.  These probes, along with screws placed on 
the cortex, detected seizures with a systemic injection of 3-MPA.  However, when these 
probes were used with local administration of 3-MPA, no seizures were detected.  This 
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result may be due to the small number of neurons exhibiting excitatory postsynaptic 
potentials (EPSPs) with the local dosing and, therefore the signal was too small to detect.   
 
5.1.2 Multiple dosing of 3-MPA 
  The effect of multiple doses of 3-MPA was investigated.  This was an interesting 
set of experiments since the long-term effects of seizures have great clinical significance.  
The 50 minute 3-MPA administration used earlier was divided into two 25 minute 
periods with two 35 minute periods where aCSF was perfused through the probe 
following each 3-MPA administration.  These experiments investigated whether neurons 
involved some protective mechanism to decrease excitotoxicity during the second 3-MPA 
administration or if neurons lost their plasticity and thus increased excitotoxicity during 
the second administration.   
 During the first administration of 3-MPA there was a 6-fold increase in glutamate 
followed by a 2.5-fold increase during the second administration.  There were smaller 
increases in both GABA and aspartate during the second administration when compared 
with the first.  There was an increase in norepinephrine during both administrations of 3-
MPA as well. 
 While these studies are preliminary, neurons seem to incorporate a protective 
mechanism to reduce the amount of glutamate released during the second administration 
of 3-MPA.  While most protective mechanisms occur over longer time periods, some 
protective mechanisms can apparently occur over the time period used in these studies. 
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5.2 Future directions 
 One of the more interesting discoveries with the local doing of 3-MPA was the 
increase in GABA.  3-MPA works by inhibiting the enzyme glutamic acid decarboxylase, 
which is responsible for the conversion of glutamic acid to γ-aminobutyric acid [29-32].  
This should result in an increase in glutamate and a decrease in GABA concentrations 
[33-37].  With a systemic injection of 3-MPA, a decrease in GABA was seen [1], 
however upon local administration of 3-MPA an increase in GABA was observed.  It has 
been suggested that this increase in GABA could be a result of the inhibitory surround of 
the seizure focus [38-41].  The inhibitory surround is a region of inhibition surrounding 
the focus of a seizure that limits excitability in the surrounding tissue [42, 43].  When 
dosing a compound through the microdialysis probe, the effected tissue region is small 
enough that an increase in GABA from the inhibitory surround could diffuse towards the 
probe and cause the increase in GABA observed.   
 Several studies utilizing microdialysis could be performed to further investigate 
the role of the inhibitory surround and the increase in GABA seen while administering 3-
MPA locally.  One probe could be used to administer 3-MPA while several other probes 
are placed in the surrounding tissue, at an incremental distance from the dosing probe to 
monitor the change in GABA in the inhibitory surround.  It would be expected that if an 
increase in inhibition in the surround is playing a role in the increased GABA at the 
dosing probe, then these increases in GABA should be larger in the surround than at the 
dosing probe, since diffusion would decrease the concentration of GABA reaching the 
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dosing probe.  Additionally, a compound which inhibits the release of GABA could be 
perfused through the non-3-MPA probes to see how that changes GABA 
neurotransmission at the 3-MPA probe. Preventing GABA release in the inhibitory 
surround would prevent the inhibition and would allow epileptiform activity to spread 
from the region directly surrounding the probe to distant tissue [40, 41].   
 Preliminary studies have been performed here to assess the neurochemical 
changes observed with multiple doses of 3-MPA.  While there is a decrease in the release 
of glutamate and GABA during the second administration of 3-MPA, this needs further 
investigation.  There are explanations for these changes on a short-term time scale, 
including feedback mechanisms, communication between glial cells and neurons, and 
synaptic vesicle sensitivity to Ca+2 [44-50].  However, there are many long-term changes, 
such as protein synthesis and enzyme and transporter regulation [51-58], that will not be 
seen over a 2-hour experiment.  Long-term awake studies must be performed, which will 
also provide more practical results, considering clinical outcomes and the long-term 
effects of epilepsy occur over a time-course of years, not hours.  
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